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Abstract 
Theranostics, a combination of therapeutics and diagnostics, spans a spectrum of research 
areas to provide new opportunities in developing new healthcare technologies and 
medicine at affordable prices. Through employing a personalized medicine approach, 
biotechnology can be tailored to the needs of an individual. Applications of theranostics 
include drug delivery carriers capable of sustained drug release and targeted delivery, 
biosensors with high sensitivity and selectivity, and diagnostic relevant entities that can 
be incorporated into the former technologies. Nanotechnology provides a suitable 
foundation for theranostics to build upon due to material-based properties; magnetism, 
biocompatibility, and quantum effects to name a few. Purpose can be incorporated and 
personalized by choosing the correct targeting ligands such as proteins and antibodies 
which provide both selectivity and specific function. An understanding of the interaction 
at the atomic level between nanoparticles and proteins can provide insight into ideal 
modification strategies to maximize the potential of both nanoparticles and the antibody 
of choice for biomedical applications. Analysis of the cellular protein interaction with 
theranostic nanotechnology provides a deeper understanding of the parameters and 
modification strategies to ensure the correct function is achieved. In the area of drug 
delivery, we investigated the functionalization strategies for the hybridization of organic 
nanoparticle drug carriers with inorganic imaging compatible nanoparticles, effect of 
size, and antibody bioconjugation on cell viability. The goal was to ensure the 
nanoparticle model minimized disruptions to the cellular structures while exacting its 
purpose for targeted localization or inducing a pharmacological effect. For biosensor 
applications, we demonstrated a non-invasive alternative to glucose measurement via tear 
glucose with high selectivity and sensitivity through the conjugation of the lectin 
concanavalin A (Con A) with fluorescent nanoparticles. Through the Forster Resonance 
Energy Transfer mechanism, we were able to measure glucose levels as low as 0.03 mM 
with high selectivity and sensitivity to minute changes in glucose concentration. These 
findings provide a better understanding of merging antibodies/proteins with 
nanotechnology and their effect in a biomedical setting. Effective management of 
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nanotechnology can potentiate a stronger physiological reaction, provide biomedical 
imaging relevance, and enhance biosensor development. 
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CHAPTER 1  
This chapter provides a general introduction to theranostics, a combination of 
therapeutics and diagnostics.1,2A literature review of current developments and 
challenges of theranostics is included in this chapter. The motivation and objectives of 
applying the benefits of nanoparticles for theranostics will be presented. 
1 INTRODUCTION 
1.1 Overview and Motivation 
Theranostics is a constantly evolving field to provide new opportunities in developing 
new healthcare technologies and medicine at an affordable price.1 The term theranostic is 
a combination of therapeutics and diagnostics, spanning a spectrum of research areas 
such as classical pharmacology and physiology to emerging fields like biotechnology and 
molecular biology.2  
Theranostics employ personalized medicine as a core value to provide the best response 
and highest safety margin to patient care.3 Variability in drug response is attributed to 
ethnic diversity, age, epigenetic factors, nutrition, and physiology; which are all routed in 
genetics.1,4 As a result of these differences from patient to patient, therapy treatments 
must be tailored to reflect genetic composition through the selection of appropriate drugs 
and treatment regimens.  
Pharmacogenetics has provided theranostics the framework to build the drug efficacy of 
personalized medicine, by studying the inherited genetic differences in drug metabolic 
pathways.5,6 Non-genetic factors such as age, organ function, and concomitant therapy 
can affect the treatment process.7 Through determining genetic makeup, clinicians are 
able to determine an individual’s therapeutic and adverse response to drugs. An example 
is the anticoagulant warfarin. Through pharmacogenetics, cytochrome P450 2C9 
(CYP2C9), the primary enzyme responsible for the metabolism of non-steroidal anti-
inflammatory drugs was identified. Variations in the VKORC1 gene that encodes the 
targeting of warfarin determines the dosage required to elicit an effect.4 In comparison to 
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Caucasians, African Americans require a higher dosage of warfarin compared to Asians, 
who require a lower dose. 
Another application of theranostics is in the diagnosis of diseases for treatment planning. 
Typical technologies include molecular biology, diagnostic radiology, and imaging to 
diagnose or prognosticate diseases for treatment planning. These technologies work as a 
cohesive unit, to determine the best course of treatment. Imaging modalities such as 
magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound, are 
typically non-invasive unless a tracer or contrast agent is required, provide an anatomical 
view of tissue, organs, and vasculature hidden by skin and bones.8–11 In conjunction with 
molecular biology, diseases can be classified by probing for molecular targets with 
antibodies for antigens, cell surface receptors, and over-expressed molecules (Figure 1-
1).12,13 HER2, the human epidermal growth factor receptor 2 oncogene, is a measurable 
and detectable tyrosine kinase amplified in 15-20% of breast cancers and gastrointestinal 
cancers.5,14 Accurate determination of the HER2 status is critical in optimizing patient 
response to clinical treatments. 
 
 
 
 
 
 
 
 
Concurrent applications for simultaneous therapy and diagnostics are possible. The 
earliest known theranostic particle was through the use of radioactive iodine-131 (I-131, 
Figure 1-1. Antibody applications for theranostics. A) Fluorophore tagged antibody 
structure for molecular biology. B) Provide cellular specificity by targeting cell surface 
ligands for identification or treatment. C) Extracellular targeting of free floating antigens 
or substrates to inhibit signal transduction. 
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131I) to provide diagnostic capabilities and therapeutic abilities.15 With a half-life of 
approximately 8 days, it is suitable to provide both pre-therapy and post-therapy imaging 
in addition to treating thyroid cancer. Other instances include radiolabeled  and/or 
optically tagged enzyme inhibitors and binding antibodies as effective tools for imaging 
and therapy of cancer.13,16 The optical tagged and radiolabeling provides a method of 
tracking and locating the molecules upon administration, whereas the antibody itself 
elicits a therapeutic response only. 
 The application of theranostics can be summarized with 3 possible scenarios: 
a) drug efficacy – assessment of drug effectiveness; 
b) diagnostics – diagnosis followed by therapy; 
c) concurrent – simultaneous application of therapy and diagnostics. 
As current medical technologies continue to evolve and improve, a deeper understanding 
of potential drawbacks and disadvantages must be understood and addressed in order to 
move forward. Disadvantages such as adverse effects of drugs,6,17–19 overcoming 
physiological barriers (e.g. blood-brain barrier, retinal-blood barrier, membranes and 
linings)20–22 and imaging limitations are pertinent in evolving pharmaceuticals.23–26 
1.2 Drug Efficacy 
The earliest and most rudimentary forms of therapeutic treatment are as old as humanity 
itself utilizing natural remedies to treat wounds and diseases.27 Remedies were prepared 
by boiling ingredients in water; a primitive liquid dosage form or mixing with 
components (e.g. fats) to enable a prolonged effect on the application site. As our 
understanding of medicine deepened and broadened, the evolution of therapeutic 
technology and diagnostic capabilities developed to reflect this. Advanced fields of 
pharmacokinetics and biopharmacy emerged from advancements in pharmacology and 
physiology. 
Early developments in pharmaceuticals consisted primarily of simple, fast-acting low 
molecular weight molecules applied orally as solid and liquids or administered by 
injection or infusion.28 These traditional dosage forms were highly time consuming to 
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make in addition to a fast drug release resulting in the high frequency of intake. The first 
generation of controlled release or rate-programmed drug release systems materialized in 
the 1970s with the aim of prolonging drug release.28,29 These formulations released the 
drug of choice at a predictable and predetermined rate to minimize intake and 
maintaining constant drug levels to maintain a therapeutic effect.27 Other forms of 
administration include pills, injections, and suppositories whose release is controlled by 
dissolution, diffusion, erosion, or osmotic mechanisms.27,30  
Typical routes of drug administration include enteric (oral, peroral, rectal), parenteral 
(intravascular, intramuscular, subcutaneous), or topical (skin and mucosal 
membranes).31,32 Therapeutics formulated for these administrative routes through 
pharmacokinetic studies, are optimized for bioavailability, efficacious delivery to the 
appropriate site, minimize toxicity, reduced side effects, and improved stability of the 
drug.32,33 These typical administrative routes have respective advantages and 
disadvantages. 
1.2.1 Challenges to Drug Bioavailability. 
Bioavailability, the rate and extent drug molecules are absorbed and become available at 
the site of action,34 can be affected by routes of administration5,32 which in turn are 
limited by biological barriers.20,21 Common routes of administration include oral, 
injections, and topical are impeded by physiological barriers which aid to naturally 
protect the human body.  
Oral delivery of drugs is limited by the gastrointestinal digestive environment, intestinal 
epithelial cells, and tight junctions.21 The gastrointestinal (GI) environment degrades 
macromolecules with the help of digestive enzymes and its acidic environment to limit its 
effectiveness.32 Furthermore, assuming the drug maintains it chemical structure, 
absorption through intestinal epithelial cells present at the small intestine and colon can 
be further impeded. The intestinal epithelial barrier presents a large absorptive surface 
requiring cell penetrating peptides for endocytosis and/or diffusion, and transcytosis to 
facilitate drug transport.21,35,36 Highly dependent on its chemical properties, a lipophilic 
drug may simply pass through the phospholipid bilayer through simple diffusion, whereas 
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polarized drugs require endocytosis as a mechanism to facilitate transport into systemic 
circulation. Drugs considered unsuitable for oral delivery or causes patient discomfort 
with swallowing may require other routes of administration such as injections or topical 
applications. 
Injections of pharmaceuticals can be subcutaneous, intramuscular (IM), or intravenous 
(IV) to yield rapid absorption and distribution by bypassing the GI tract. By far IV 
administration produces the quickest response, though systemic circulation can rapidly 
dilute the drug. IM administration in comparison has a longer duration of effect as its 
formulation is designed to provide slow, sustained release over a period of time into the 
blood stream.37  IV injections can prevent local irritation, induration, skin discoloration, 
inflammation, and granuloma formation associated with subcutaneous and IM injections 
but may cause discomfort as it is invasive.37,38  
Topical administration replaces the need for invasive drug administrative techniques 
which may cause discomfort. Topical applications include lotions, creams, and eye drops 
applied to a localized area rather than systematically.17,39 Applications to the skin is 
limited by the outermost few microns of skin, the stratum corneum (SC), is the least 
permeable of skin layers.40 Permeability from the skin’s surface to the site of action is 
limited by the lipophilicity of the drug to diffuse through the SC and its aqueous 
solubility once through the barrier. Diffusion is key to the transport of topical drugs 
through the skin, but requires high concentrations with the risk of skin irritation.39,41  
Regardless of the method of drug delivery, the key limitation to an appropriate route of 
administration lies with a patient’s comfort as well as the bioavailability of the drug once 
it is systematically absorbed. Once absorbed, the remaining limitation lies in the drug’s 
ability to diffuse to the site of action from the site of administration. 
1.2.2 Therapeutic Window and Drug Distribution 
The therapeutic window or safety window refers to a range of doses that defines efficacy 
and toxicity commonly studied by pharmacodynamics.42,43 Efficacious effect at the site of 
action requires a minimal threshold of the drug to illicit its therapeutic effect; however 
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Figure 1-2. Physical barriers to successful drug delivery. A) Natural barriers such as the 
blood-brain barrier and blood-retinal barrier are composed of tight junctions preventing 
the diffusion and transfer of solutes through the barrier to the tissue of interest. B) 
Diffusion from the tissue through fenestrations in the capillary endothelium into the 
blood stream or vice versa is caused by the concentration gradient of solutes. 
natural physiological processes may hinder a drug's ability to be delivered. Processes 
such as hepatic first pass,39,42,43 loss by diffusion through fenestrations into the capillary 
endothelium,36,44 and previously mentioned barriers in addition to limitations of drug 
administration routes all contribute to lowered drug concentrations (Figure 1-2).34   
 
 
 
 
 
 
Upon oral administration, drug elimination is hindered by the first pass effect or pre-
systemic metabolism where drug concentration is greatly reduced by hepatic portal 
system before reaching systemic circulation.42,45 This effect can occur in the GI tract but 
the liver is mainly responsible for drug metabolism for elimination as it has the highest 
metabolic biotransformation capacity.45 The splanchnic system’s organs are arranged 
such that the intestines and liver act as a barrier for drug distribution.  
 
Diffusion between the interstitial space and the capillary for system circulation in 
addition to the capillary endothelium are barriers to overcome. The diffusion 
pharmacokinetics can be assessed using a compartment model of the vascular circulation 
through capillaries and interstitial space.32,36 Essentially the flux of drug particles drive 
diffusion through a biological membrane into either side of the compartment model 
depending on the concentration gradient. In the case of IV, the first pass effect is avoided 
leading to direct diffusion into the site of action. However for IM administration, 
localization  at the site of action for drugs smaller than 69 kDa becomes ineffective, as 
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capillaries in general circulation possess fenestrated gaps between 6-7 nm for 
transcytosis.36,46 
1.2.3 Drug Effectiveness and Adverse Effects (references) 
A drug’s effectiveness is evaluated on potency, efficacy, or effectiveness.47 Potency 
measures the minimal amount of drug required to produce an effect. Efficacy measures 
the drug’s capacity to produce an indicated effect or the strength of the indicated effect. 
The effectiveness however, a measure of how well a drug works, encompasses potency, 
efficacy, and potential adverse drug reactions. Effectiveness of a drug for pharmaceutical 
applications requires risk-benefit analysis, dosage scheduling for duration of effect, and 
adverse effects. 
Adverse effects are a general umbrella term to describe unintended effects that occur 
within the therapeutic range – the dosage range in blood plasma or serum required to 
achieve a therapeutic effect. Adverse effects are common forms of iatrogenic injury 
resultant of overdosing accidentally or enhanced absorption by alternate routes during 
appropriate use, and at times interactions between multiple drugs.17,18 Aside from 
overingestion, overdosing can occur through topical and systemic routes.17 Careful 
control of drug administration routes and dosages are required to maximize effectiveness. 
1.3 Diagnostics 
Diagnostic components of theranostics is realized by molecular imaging techniques, 
medical imaging modalities, and immunoassays.12,48 These techniques aid disease 
diagnoses from the molecular level to the macroscopic level such as the identification of 
specific cell markers to the localization of anatomical features. The segmentation of 
regions of interest in diagnostic imaging is complemented by immunoassays for disease 
confirmation. 
1.3.1 Magnetic Resonance Imaging 
Magnetic resonance (MR) relies on certain atomic nuclei to absorb and emit radio 
frequency (RF) energy when placed in an external magnetic field. Hydrogen atoms being 
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the most abundant nuclei in biological organisms, found in water and fat, are often used 
to generate a detectable RF signal which can be translated into an image. 
Atomic nuclei possess spin or intrinsic spin angular momentum rotating about an axis at a 
constant rate.49 MR measurements consider a collection of similar spins as a single entity. 
Consider an arbitrary volume of hydrogen atoms (protons) placed into an external 
magnetic field (B0). The protons will precess about the magnetic field or rotate 
perpendicularly. Their axis of procession is parallel to B0 even if the proton vectors are 
tightly slightly away. The rate or frequency of precession shown in Equation 1-1 is 
proportional to the strength of the magnetic field is expressed by the Larmor Frequency.49 
Equation 1-1 
𝜔0 =
𝛾𝐵0
2𝜋
 
Where Larmor Frequency (ω0) is expressed in megahertz (MHz) and B0 in tesla (T). The 
atom specific γ, the gyromagnetic ratio, is expressed in s-1T-1. As a result, the protons 
have a net magnetization (M0) that is parallel and proportional to B0 (Equation 1-2)
50. 
Equation 1-2 
𝑀0 = 𝜒𝐵0 
The magnetic susceptibility (χ) is a dimensionless proportionality constant characterizing 
a material’s readiness to develop a magnetic moment on exposure to an external magnetic 
field. Positive values of χ are called paramagnetic materials, whereas negative are 
diamagnetic.51 
In MRI, the net magnetization (M0) is manipulated with a short RF burst of excitation 
energy (B1). During the pulse, the protons absorb a portion of energy at its Larmor 
Frequency resulting in a shift in the vector of M0 such that it is no longer perpendicular to 
B0. If enough energy is absorbed, M0 may rotate into the transverse plane due to 90° 
pulse. Once B1 is turned off, the protons will realign with B0 while emitting energy at ω0 
(Figure 1-3a).49,50  
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Figure 1-3. Paramagnetic interaction in Magnetic Resonance Imaging. A) Precession of 
protons in a magnetic field. B) Paramagnetic materials, materials with a magnetic 
susceptibility greater than zero (χ>0), will influence the surrounding protons by pulling 
the magnetic field inwards resulting in the increase of relaxation rates (T1 and T2 rates) 
and signal intensity on T1-weighted images. 
Magnetic resonance imaging can provide anatomical and morphological references, as 
well as in vivo bioactivity for disease diagnoses based on the detected radio waves.23,25 In 
addition, heavy metal-based contrast agents are valuable assets in enhancing contrast in 
images and perfusion analyses.9,52 Monitoring of vascular, cerebral, and tumour perfusion 
is possible by deriving tracer concentration-time curve.9,52,53  
Gadolinium-based compounds are typical T1 weighted MRI contrast agents, a chelated 
paramagnetic metal, which enhances the longitudinal relaxation of tissue’s net 
magnetization vector.50 The paramagnetic property is a result of unpaired electron spins 
in certain electron orbital shells of transition and lanthanide metals which exhibit a 
different magnetic susceptibility that is higher than protons.49 Protons in close contact 
with the paramagnetic material experience both the magnetic field of the contrast agent 
and B0, resulting in an increase in perceived magnetic fields, thus altering T1 imaging. 
The resulting image does not visualize the contrast agent but rather the MR signal of 
surrounding protons have a shortened relaxation time.50   The paramagnetic materials, 
which have the positive χ, pulls the magnetic field into the materials whereas objects with 
negative χ pushes (Figure 1-3b).51  
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1.3.1.1 Challenges to Magnetic Contrast Agents 
Application of gadolinium-based contrast agents can result in adverse reactions. Heavy 
metal toxicity is a possible adverse effect if gadolinium is isolated in its free ionic form 
(Gd3+) where it can precipitate in various tissues with no natural excretion pathway. A 
weak binding between Gd  and its chelator, as determined by its dissociation constant, can 
result in transmetallation where it is replaced by endogenous iron, calcium, zinc, and 
copper.23,24,54 Upon release, Gd can bind phosphates to interfere with cation channels 
leading to splenic degeneration, liver necrosis, enzyme inhibition, interference with 
synaptic transmitters/receptors, and hematological abnormalities.23 Immediate adverse 
hypersensitivity reactions are possible in 0.06-0.3% of patients within 1 hour of contrast 
exposure, resulting in allergy-like symptoms and physiological responses such as nausea, 
vomiting, and altered taste.54  
Though gadolinium-based contrast agents have been introduced into clinical practice 
roughly 3 decades ago, recent pharmacokinetic findings from analytical techniques have 
detected the presence of insoluble gadolinium salts (eg: gadolinium phosphate, 
bicarbonate) in the brain; normally undetectable by both T1 and T2 imaging.55 Cases of 
neurotoxicity as reported by Hui et al.56 and Maramattom et al.57  is resultant of 
gadolinium accumulation in patients receiving repeated or large doses of contrast agents.  
Accumulation has been reported within the extracellular neural tissue, endothelial walls, 
and basal ganglia, with impaired renal function has been confirmed as a factor 
contributing to the increased accumulation.24,55,58 It is known intravenously administrated 
Gd slowly pass through the blood brain barrier through proposed mechanisms involving 
transmetallation, specific metal transports, passage through the cerebral spinal fluid, 
perivascular spaces, and even the glymphatic system.24 This unexpected finding is 
attributed to nephrogenic systemic fibrosis, encephalopathy, and inhibition of regular 
neurological function (eg: visual memory and reasoning, reading comprehension, and 
math abilities).23,58 
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1.4 Concurrent Theranostic Applications 
Molecular imaging is an effective demonstration of concurrent theranostic applications – 
to provide critical diagnostic information with regards to anatomic or cellular targets to 
induce a therapeutic effect in vivo and in vitro. An example of early clinical applications 
utilizes traditional nuclear medicine for the treatment of differentiated thyroid cancer. 
Radioactive iodine (ex: I-131), dating back to the mid-1940s, was the first theranostic 
agent to provide both diagnostic and therapeutic capabilities.15,48 This high energy tracer 
was used diagnostically for both pre-therapy imaging and radiopharmaceutical post-
therapy CT imaging due to its 8 day half-life. As an adjunct therapeutic treatment, 131I 
was used in ablative therapy for differentiated thyroid cancers and metastatic diseases.48 
With advancements in molecular biology, new approaches emerged through the use of 
therapeutic drugs or antibodies to achieve specificity coupled with alternative modes of 
imaging.  
Biocompatible applications require the direct conjugation of fluorescent dyes, 
radionuclides, and contrast agents to antibodies or enzymes to customize a trackable 
therapeutic agents to interfere with aberrant targets or disease pathways.16,59–61 
Radionuclides have diverse applications aside from CT as they are compatible with 
Positron Emission Tomography (PET, ex: 18F)62 and Single-Photon Emission Computer 
Tomography (SPECT, ex:  99mTc, 131I )13,61 which provide metabolic and functional 
information to complement CT and MRI anatomic images. Current theranostic 
applications for cancer utilize antibodies to target the cell membrane or ligands with the 
addition of radionuclides to increase treatment efficacy.16 These same conjugates can also 
be applied to immunohistochemistry for cell biomarker assessment, such as the Hercep 
Test for breast tumors.5,14 In clinical practices, scans of the radionuclides may be 
performed repetitively to assess modulation over time and the bioavailability measured. 
The same technology can be applied to MRI by conjugating the therapeutic antibody 
directly to the gadolinium chelator to promote localization within tumours. As Orcutt et 
al. have demonstrated, with DOTA chelated with various radionuclides (yttribum, 
lutetium, and gadolinium) modified with the monoclonal antibody 2D12.5 to enhance 
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accumulation within the tumor.59 Grum et al. presented a two domain fusion protein 
Zarvin capable of binding to a therapeutic immunoglobulin G antibody for targeting 
while facilitating high affinity binding sites for Gd.63  
A fluorescent alternative can be produced for superficial and in vitro applications as 
demonstrated by fluorescent microscopy, which has widely been used in the fields of 
molecular biology, immunochemistry, and assays to identify proteins of choice.64 The 
same can be applied by conjugating fluorescent dyes to therapeutics which can be 
antibodies, microRNAs, antibiotics to study their effects.12,65,66 As Oosten et al. have 
demonstrated, fluorescently labelled vancomycin able to identify gram-positive bacterial 
infections in a murine model in vivo and a human cadaver in real time. As for miRNA, it 
is understood their dysregulated expression is implicated in various human diseases. The 
addition of a fluorescent tag, provides valuable information in gene expression and 
results in further understanding pathways to target in cancer.65 Its implementation can 
extend to cardiovascular diseases, neurological diseases, and viral diseases.67–69   
1.4.1 Challenges to Concurrent Applications 
Though current diagnostic imaging techniques have proven to be effective, there are 
limitations which may inhibit a product to reach its maximum potential. As previously 
mentioned, the application of gadolinium-based contrast agents can result in adverse 
effects. Another limitation in order for the contrast agent to be effective is to achieve a 
minimal threshold to which it can yield its effect. The chance of unnecessary 
overexposure to ionizing radiation when using CT or radioisotopes have also prompted a 
shift towards other imaging modalities such as MRI and fluorescence.70 
Fluorescence imaging, in addition to being a nonisotopic method of detection, can open 
new possibilities for ultrasensitive high-resolution detection. One concern is 
photobleaching, where a fluorophore loses its fluorescent signal over time as a result of 
repetitive stimulation.71,72 In clinical applications, fluorescence imaging lacks tissue 
penetration as the very small structures and boundaries in cells absorb and scatter photons 
in the visible range.73 The reciprocal of the absorption coefficient (µa) and scattering 
coefficient (µs), with units cm
-1 or mm-1, yields the mean free path or the average distance 
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traveled. Cytochroms and hemoglobin are the most common absorbers in cells, resulting 
in a mean free path of less than 1cm (µa>> 1cm
-1). The fluorescence excitation 
wavelength, typically 350 nm to 800 nm, can result in genotoxic effects-damage to the 
genetic structure.74 Though the mechanisms of light-induced genotoxicity vary by 
wavelength, the implications of mutagenicity and carcinogenicity resultant of light 
irradiation is clear.75–77 
1.5 Nanoparticles for theranostics 
Early application of nanoparticles dates back to the 9th century in Mesopotamia and the 
middle ages where colloidal silver and gold was used to produce luster. This metallic film 
was applied to the transparent surface of a glazing to provide a glittering effect on the 
surface of pots.78,79 This film was found to resist atmospheric oxidation and weathering. 
The metal salts in combination with vinegar, ochre, and clay under a reducing 
atmosphere and a kiln heated to 600°C was the ideal environment to form nanoparticle 
aggregates with specific colours and optical effects.79 It was Faraday who first provided 
the scientific description for the observed optical effects in 1857.80,81  
It was not until the last few decades that our knowledge and understanding in science 
brought nanoparticles to the forefront of enhancing biomedical technology. Partially 
because of the diversity in material composition, these same particles exhibit size-related 
properties at the nanoscale (10-9 m) not seen in their bulk form; quantum confinement,82–
86 surface plasmon resonance,87,88 superparamagnetism,89,90 paramagnetism,91,92 and high 
surface area to volume ratio (Figure 1-4).93 As a result, these material dependent 
characteristics can be tailored or modified for specific applications or integrated together 
for more versatile biomedical purposes.  
One key advantage of nanoparticles for biomedical applications such as; biosensors, 
multimodal compatible imaging, and drug delivery is the potential for personalized 
medicine at a fraction of the cost of current healthcare. A nanosized particle customized 
to meet the needs of an individual patient may potentially cross natural barriers and enter 
tissue through different portals of entry or interact with biomolecules in the blood.94 In 
the case of cancer, molecular targets and chemotherapy drugs are often rendered 
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Figure 1-4. Enhanced surface area to volume ratio. The increased surface area to volume 
maximizes ample surface area for nanoparticle post-synthesis modifications. 
ineffective as the cancer cells will evolve ways to survive one oncogenic pathway.95 It is 
more beneficial to target several pathways simultaneous with a drug cocktail than to 
target an isolated pathway. Nanoparticles offer the potential to not only encapsulate and 
provide sustained release of cancer drugs, but also aid to localize the cells within tumours 
as they lack lymphatic drainage to eliminate the nanoparticles enhanced permeability and 
retention effect (EPR).96 
 
 
 
 
 
 
 
The material-dependent properties extend beyond those of metals. Organic biodegradable 
polymers (ie: gelatin, chitosan, liposomes)97–99 and synthetic biocompatible polymers (ie: 
poly-lactic acid, poly-caprolactone)100,101 exhibit material specific set of characteristics 
perfect for drug encapsulation and sustained drug release. Unlike its metallic counterparts 
which are synthesized into a crystal lattice solid core organized at the atomic level, 
biodegradable and biocompatible nanoparticles form hollow shells with morphological 
pores in some cases. Encapsulation process, release profiles, and even pore size can be 
controlled during the synthesis process to tune its physical characteristics.102–104  
The development of nanoparticles is a revolutionary advancement for biomedical 
technology. The nanoscale particulates exemplify a unique set of characteristics through 
reshaping materials in current technologies such as gelatin for soft gel encapsulation105 or 
gadolinium for imaging.106 Applications of nanoparticles in biotechnology include 
improved drug delivery and enhanced accumulation by EPR, new imaging technologies, 
and highly sensitive biosensors that can mitigate negative effects or enhance overall 
effectiveness. 
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1.5.1 Drug Delivery 
Nanoparticle drug encapsulators demonstrate various advantages over current delivery 
technologies. Varying in material, drug delivery nanoparticles offer both biodegradability 
and biocompatibility. These systems provide a matrix for therapeutic immobilization, 
adsorption, bioconjugation/attachment, and encapsulation, allowing for controlled release 
profiles which directly affects drug bioavailability and its therapeutic index.103,104 The 
controlled release profiles differ according to the method and conditions of synthesis, 
base material, and potential modification. The consensus regardless of material and 
method demonstrates the following advantages: 1) drug loading in nanoparticles achieved 
is relatively high with the preservation of drug activity, 2) provide site-specific 
localization with ligand modification, 3) improve pharmacokinetics and reduced adverse 
reactions, and 4) increased stability of drug by protecting against chemical and enzymatic 
degradation, and elimination.30,32,103,104,107 
Organic nanoparticles synthesized from animal proteins (ex: gelatin, collagen, chitosan) 
have a low cytotoxic end product (metabolite or product of degradation).98,108 As 
demonstrated by Vandervoort et al., the successful encapsulation of a drug was dependent 
on the solubility of the drug of choice in the synthesis environment.109 Exemplified by 
gelatin nanoparticles synthesized by a desolvation method, the dehydration of protein in 
an aqueous solution with an organic solvent (alcohol or acetone) to change from a 
stretched to coiled conformation, demonstrated a higher encapsulation efficiency for 
hydrophilic drugs rather than hydrophobic drugs. Synthesis methods employed for drug 
encapsulation include desolvation, coacervation, emulsification, ionic gelation and 
nanoprecipitation.97,104,110  
Regardless of material and synthesis method, drug loading and drug release are 
key factors for a successful drug delivering nanoparticle. Firstly, drug loading is achieved 
by incorporation during the synthesis process or post-synthesis by mixing the carrier with 
a concentrated drug solution (adsorption or absorption).111 Drug loading is characterized 
by the ratio of drug encapsulated or absorbed (moles or mg) per nanoparticle weight 
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(mg), which can be optimized by measuring the encapsulation efficiency or ratio of drug 
loaded to the total amount of drug used (Equation 1-3).36 
Equation 1-3 
𝐸𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (%) =
(𝑊 − 𝑤)𝑋100
𝑊
=
𝐴𝑚𝑜𝑢𝑛𝑡 𝐿𝑜𝑎𝑑𝑒𝑑
𝑇𝑜𝑡𝑎𝑙 𝐴𝑚𝑜𝑢𝑛𝑡 𝑈𝑠𝑒𝑑
𝑋100 
Drug release however is governed by not only the solubility of the drug, but the diffusion 
through the nanoparticle matrix or pores, nanoparticle degradation, and the processes of 
erosion and diffusion.32,111 Typical release is governed by zero order kinetics or first 
order kinetics, a function of time or concentration, respectively (Table 1-1).32,112  
 
Table 1-1. Drug Release Kinetics 
Zero Order 
𝐶𝑡 = 𝐶0 + 𝐾0𝑡 
First Order 
ln 𝐶𝑡 = 𝑙𝑛𝐶1 − 𝐾𝑡 
t: time, C0: initial burst release of drug, K0: zero-order rate constant, C1: initial 
concentration of drug, K: first order rate constant 
 
Furthermore, the surface chemistry of protein nanoparticle can be functionalized due to 
the presence of surface functional groups to affect biodistribution, biocompatibility, and 
stability.113,114 Typical surface functional groups of the protein (amine, carboxyl, and 
thiol groups) exposed by the conformational changes of the protein macromolecules can 
be crosslinked to provide stability and/or bioconjugation of ligands (targeting moieties 
and therapeutic protein).107,115,116 As a result of post-synthesis surface modifications, 
290003476271these nanoparticles demonstrated enhanced cellular uptake and 
association. Balthasar et al., demonstrated the attachment of biotinylated anti-CD3 
antibodies to the surface of gelatin nanoparticles were promising carriers for delivering 
drugs to T-lymphocytes through the formation of an avidin-biotin complex.117 The 
addition of polyethylene glycol (PEG), an example of a targeting moiety, to the surface of 
nanoparticles can lengthen circulation time of drug loaded nanoparticles and decrease 
immunogenicity to increase bioavailability and biodistribution in patients.118,119 
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1.5.2 Imaging 
In contrast to organic nanoparticles, metallic nanoparticles exhibit a completely different 
set of properties suitable for imaging such as downconversion fluorescence, upconversion 
fluorescence, paramagnetism, and superparamagnetism.83,84,90,92 Applications for such 
imaging technology not only address the limitations of current imaging technologies such 
as toxicity, adverse reactions, and photobleaching, but allow for the sensitivity to track 
individual cells and tuning of detectable optical spectra. Voura et al., demonstrated the in 
vivo application of quantum dots to study the extravasation of tumour cells as a model for 
tracking metastasizing cancer cells.82 The physical composition of the nanoparticle, 
transition and post-transition metals (ie: iron, cadmium, lead, indium) or lanthanides (ie: 
gadolinium, erbium, ytterbium), attributes to the various optical and magnetic properties 
measured or observed.72,89,120 
1.5.2.1 Quantum Dots 
Semiconductive nanoparticles or quantum dots (QDs) exhibit quantum confinement 
properties resistant to photobleaching as observed in fluorescent dyes.121,122 The resultant 
photobleaching involves the triplet state, where upon photon absorption, a fluorophore 
transits from the ground to first singlet-excited state.123 This can also transition into the 
triplet-excited state, associated with higher energy (>1 eV) and longer lifetime (~102 µs), 
facilitates chemical reactions that results in fluorophore bleaching.123–125 The 
photoluminescence observed is the result of quantum confinement in the nanoscale 
dimension where an electron is confined to dimensions smaller than its Bohr radius. The 
density of states decreases near the conduction band and valence band to form discrete 
quantifiable energy states or band gaps characterized by an electron-hole pair (Figure 1-
5). This band gap energy is responsible for the observed emissions that can be tuned by 
controlling nanoparticle size; an increased energy is associated with decreasing 
nanoparticle size.122,126 With a broad excitation spectra, an exciton (electron to be 
excited) will jump into the covalent band or excited state, leaving a hole. Upon returning 
to ground state and recombining with the hole, electromagnetic energy with a narrow 
profile will be emitted within the UV to near infrared spectra.126 
18 
 
 
Figure 1-5. Band gap energy of fluorescent quantum dots. QD fluorescence is defined by 
its band gap, which corresponds to its size, to produce the detected fluorescence. A larger 
band gap is associated with a smaller QD to cause a blue Stokes Shift resulting in a 
higher energy emission. 
QDs are synthesized from organometallic precursors at temperatures of 300°C or higher 
and varying nucleation duration to control the growth of nanoparticles in a solvothermal 
reaction.71,82 Nanoparticles from both group II-VI (eg: CdSe, CdTe,  and CdS) and group 
III-V (eg: InP and InAs) have been extensively studied.71,121 This method of synthesis 
requires surface functionalization to render them water-soluble and biocompatible.127,128  
 
 
 
 
 
 
 
 
 
 
With a modicum of success, QDs have demonstrated biocompatible applications for 
cellular imaging and molecular biology. Modified QDs exhibited internalization by cell 
lines such as HeLa, UTA-6 osteosarcoma, hepatocytes by receptor-mediated endocytosis 
or phagocytosis demonstrated low cytotoxicity.70,72,120,128,129 Furthermore, upon 
introduction into murine models, QDs were visualized through the skin in capillaries 
hundreds of micrometers deep.127 In murine with C4-2 tumour xenografts, the QDs were 
uptaken and retained within the tumor cells.72,84 
1.5.2.2 Upconversion Nanoparticles 
Where QDs exhibit a Stokes shift when excited, emitted photon with a longer wavelength 
and lower energy than the absorbed light, upconversion nanoparticles (UCNPs) 
demonstrate the opposite (Figure 1-6).130 Upconversion through a multiphoton 
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Figure 1-6. Conventional downconversion and upconversion luminescence. A) 
Conventional downconversion luminescence is characterized by a higher energy 
excitation photon and a lower energy emission photon (hv1>hv2). B) Upconversion 
luminescence, through a multiphoton excitation method will cause transfer the lower 
energies of multiple excitation photons to a higher energy emission photon (hv3> hv1, 
hv2). 
conversion process transmits multiple lower energy photons from near-infrared (NIR) 
lights to a higher energy photon which is emitted.85,86 Similar to QDs, UCNPs are 
synthesized at high temperatures through a solvothermal or hydrothermal reactions with 
lanthanide pairs to produce the upconversion phenomena from NIR light (700-1700 
nm).86,120,131 The resultant lanthanide dopant pairs, donors (ex: Yb3+) and acceptors (ex: 
Tm3+, Pr3+, and Er3+), form an energy-transfer network within a single 
nanoparticle.85,106,131–133  
 
 
 
 
 
 
 
 
 
 
The application of NIR UCNPs for biotechnology is desirable for its “optical 
transparency window” which provides deeper light penetration and reduced 
photodamaging effects.106,133,134 Photodamage or phototoxicity can result from the 
application of higher energy light such as UV as an excitation source resulting in damage 
to DNA.75,77,135 The cytotoxicity of the UCNPs are not only less than that of QDs, but 
possess  a stronger fluorescence signal as well.134 In comparison, the lanthanide pairs of 
Yb/Er or Yb/Tm has been reported to show seven orders of magnitude higher than that of 
CdSe-ZnS QDs.127,134 
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1.5.2.3 Gadolinium-based contrast agents and Bimodal Imaging 
The next generation of gadolinium-based contrast agents is a potential for bimodal 
magnetic resonance and upconversion fluorescence imaging. The crystal lattice structure 
of fluoride-based nanoparticle provides the optimal stability to prevent lanthanide ion 
dissociation.120,134,136,137 Similar to the synthesis of upconversion nanoparticles, the core 
constituent of NaGdF4 that provides magnetic resonance compatibility is doped with 
lanthanide pairs for upconversion fluorescence.138,139  
Applications for cellular and tissue imaging as alternatives to organic dyes and QDs for 
luminescent probes have demonstrated success.140,141 Wysokińska et al. reviewed the 
potential interactions of NaGdF4:Yb
3+, Er3+ UCNPs with murine macrophage and 
fibroblast cells.142 They concluded the addition of a PEG coating or silica shell greatly 
improved the viability of cells, but also enhanced the interaction. Other groups have 
demonstrated the successful non-toxic interactions between 16HBE, HeLA, MCF-7, and 
KB cells after incubation with UCNP.143,144 In vivo murine models with and without 
tumour xenografts, UCNPS exhibited localization within the tumour and liver, 
demonstrating its effectiveness as a contrast agent.91,106,145 Furthermore, Zhou et al. 
compared the NaGdF4-based UCNPs to Magnevist
® (Gd ions chelated to 
diethylenetriaminepentaacetic acid) and found UCNPs contained a higher concentration 
Gd resulting in a stronger T1-weighted MRI signal.106 
1.6 Motivation 
The potential of nanoparticles to enhance biomedical applications is massive. By 
themselves, nanoparticles are a blank slate, capable of molding, and designing the ideal 
composition for specific applications.  In combining imaging compatible nanoparticles 
coupled with a targeting ligand/antibodies and potentially in conjunction with a drug 
encapsulating reservoir, the ideal theranostic vehicle can be designed to provide both 
purpose and cellular specificity.94,146 As individual components, it is understood 
nanoparticles possess far superior properties than can address the shortcomings of current 
biomedical technology. However as a whole, much is still to be investigated to 
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characterize cellular interactions, identify ideal synthesis and modification procedures, 
and compare its effectiveness to current technologies.  
On the other hand, proteins and antibodies provide both specificity and function to the 
nanoparticle where it lacks. First pioneered in the 1960s, nanoparticles were 
conceptualized as a “magic bullet” to target specific disease with accuracy and 
specificity.29 One vital proposed clinical application of nanoparticles is for the treatment 
of wet age-related macular degeneration (AMD), characterized by abnormal 
neovascularization in the choroid of the eye, prevalent in those aged 50 or older.147,148 
Currently several anti-vascular endothelial growth factors have been proven to be 
effective against neovascularization in AMD and improve visual acuity.148–150 However, 
the effects demonstrated last several weeks, prompting repeated dosages injected into the 
eye to control the neovascularization. Nanoparticles have been proposed to deliver 
nucleic acid fragments such as oligonucleotide and neurotrophic factors to inhibit VEGF 
secretion and mRNA expression as alternative treatments to increase time between 
dosages.147 Furthermore, cell adhesion molecules or receptors are required to minimize 
unwanted side effects.147  
The nanoparticle and protein conjugation process, a molecular level understanding, is 
pertinent to ensure the successful incorporation of the individual components into a 
theranostic vehicle as a cohesive unit. A thorough analysis is required to assess the 
potency of the theranostic vehicle especially if intended for in vivo or clinical 
applications. The cellular level of understanding the nanoparticle and cellular protein 
interaction is relevant to ensure the desired outcome is achieved with minimal adverse 
effects. 
1.7 Thesis Objectives 
The overarching theme of this thesis is to understand effects of the interaction between 
nanoparticles and proteins at the molecular level (ie: synthesis and bioconjugation 
strategies) and at the cellular level (ie: cellular interaction) and develop novel biomedical 
applications in the realms of drug delivery, medical imaging, and biosensing. The 
specific objectives of each chapter of this thesis are introduced below. 
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In Chapter 2, the objective was to quantitatively assess our hybridized drug delivery 
model composed of a gelatin nanoparticle drug reservoir and CdSe QDs modified with a 
non-cell specific targeting antibody anti-human immunoglobulin G. The goal was to 
assess the cytotoxic effects on U20S human osteosarcoma cell derived UTA-6 cells as a 
proof of concept for potential drug delivery applications with fluorescent tracking. We 
hypothesized our model would associate on the surface of the cells to provide a stable 
reservoir for drug release. 
In Chapter 3, the objective was to assess and compare the gelatin nanoparticles model in 
Chapter 2 of different sizes functionalized via different strategies and its influence on the 
compatibility with UTA-6 cells. We hypothesized both size and modifications order are 
crucial to the success of the theranostic vehicle as a whole. We identified the location of 
the nanoparticle model relative to the cell and contrasted the larger to the smaller 
nanoparticle model for effectiveness as a non-cytotoxic drug carrier. 
In Chapter 4, the objective was to develop a theranostic model with bimodal tracking 
capabilities and anti-VEGF functionalization for anti-angiogenesis treatment. The 
proposed model core, NaGdF4: Er, Yb, is compatible with both magnetic resonance and 
fluorescent imaging. We assessed the model as a whole to inhibit angiogenesis in human 
umbilical vascular endothelial cells stimulated to exhibit angiogenic properties such as 
migration and proliferation. We hypothesized the model would provide the relevant 
theranostic properties suitable for in vivo tracking as it exerts its therapeutic effect. 
In Chapter 5, the objective was to develop a safe and non-invasive biosensor for the 
detection of tear glucose. We proposed the use of upconversion nanoparticles for Förster 
Resonant Energy Transfer (FRET) as a means to detect changes in tear glucose on a 
contact lens-based substrate fluorometrically. Tear glucose can reflect the blood glucose 
concentration, albeit rather slowly. We assessed our sensor’s sensitivity and compared 
that to a glucose meter that is commercially available. We hypothesized our glucose 
biosensor is non-cytotoxic and can detect low levels of tear glucose with high accuracy. 
In Chapter 6, an overview and summary of the important findings and conclusions of 
Chapters 2-5 will be presented. The limitations of current technology will be presented 
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and discussed with potential solutions. The thesis ends with a roadmap for future studies 
that could build on the groundwork of knowledge generated by this research. 
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CHAPTER 2  
To quantitatively assess our hybridized drug delivery model composed of a gelatin 
nanoparticle drug reservoir and CdSe QDs modified with a non-cell specific targeting 
antibody anti-human immunoglobulin G. The goal was to assess the cytotoxic effects on 
U20S human osteosarcoma cell derived UTA-6 cells as a proof of concept for potential 
drug delivery applications with fluorescent tracking.  
The contents of this chapter was previously published in the Proceedings of the 14th 
IEEE International Conference on Nanotechnology: WH. Tse, L. Gyenis, DW. Litchfield, 
and J. Zhang. Engineering Large Gelatin Nanospheres Coated with Quantum Dots for 
Targeted Delivery to Human Osteosarcoma Cells with Enhanced Cellular 
Internalization. Proceedings of the 14th IEEE International Conference on 
Nanotechnology 2014; 672-677. doi: 10.1109/NANO.2014.6967978 
2 ENGINEERING LARGE GELATIN NANOSPHERES 
COATED WITH QUANTUM DOTS FOR TARGETED 
DELIVERY TO HUMAN OSTEOSARCOMA CELLS 
WITH ENHANCED CELLULAR INTERNALIZATION 
2.1 Introduction 
Larger sized nanoparticles, nanospheres (>250 nm), synthesized from different polymers 
such as gelatin1,2 and chitosan1,3 have been extensively studied as carriers for drug 
delivery due to their superior biocompatability. Most studies focus on drug release 
profiles dependent on various sized nanocarriers.4,5 To realize optimal results of cancer 
treatment, suitable surface modification is required to deliver drug-loaded nanospheres to 
a targeted area.6 Gelatin nanospheres (GNs) have been used to deliver genes and different 
drugs in in vitro studies7 and animal models8 by modifying the surface potential to 
become cationic. Quite recently, efforts on using nanomaterials in theranostics have been 
attempted by loading fluorophores into these biopolymer nanoparticles for simultaneous 
cell-tracking and drug-delivery.9 Theranostics, a combination of diagnostics and therapy, 
can be applied in three scenarios: a) pharmacogenetics; b) treatment planning; or c) 
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simultaneous diagnosis and therapy.10,11 Properly engineered nanospheres, as a platform, 
have the potential for co-development into a drug carrier with bio-imaging capabilities, as 
described in the latter scenario. 
Compared to the nature of synthetic organic dyes, quantum dots (QDs) have high 
fluorescence intensity, minimal photobleaching, and tunable emission peaks, i.e. the 
smaller the QDs the larger the associated band gap which correlates to a more blue 
fluorescence, and the reverse results in a more red emission.12,13 Unfortunately, they can 
be cytotoxic; especially those synthesized from cadmium.14 Modified QDs have shown 
improved stability,15 reduced cytotoxicity,16 and potentials in in vivo tumour targeting 
studies.17 
Immobilization of small quantities of QDs onto biopolymer nanospheres through 
covalent bonds may reduce the cytotoxicity of QDs, improve photostability, and impose 
fluorescent properties onto biopolymer nanospheres for easy detection. Previous studies 
show GNs demonstrate a long circulation time and high accumulation in tumour 
tissues.10,18 Gelatin is considered a suitable base material for QD immobilization or 
bioconjugation due to the various functional groups available on its surface for post 
synthesis modification, including hydroxyl (-OH), amino (-NH2), and carboxylic (-
COOH) groups.19 The varying functional groups offer many possibilities for QD-
immobilization onto the surface of nanocarriers.  
Furthermore, these same functional groups allow for the bioconjugation of antibodies for 
targeted drug delivery However, few studies provide the quantitative analysis on the 
surface modification and bioconjugation of nanosized materials. In addition, it is noted 
that the amount of drug payload encapsulated in larger nanoparticles is easy controlled as 
compared to that of smaller nanoparticles. Unfortunately, it is yet quite challenging to 
transport nanomaterials with large diameters >150 nm into cells due to the selective and 
semipermeable cell membranes.20 Therefore a larger sized hybridized inorganic and 
organic nanoparticles capable of imaging and targeted drug delivery with good cellular 
internalization would be the next step in the evolution of a functional theranostic 
molecule. The capacity our hybrid nanospheres will be assessed on human osteosarcoma 
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cells, bone cancer which commonly develops during the teenage growth spurt.21 Human 
osteosarcoma cells are normally used in biomedical studies on either targeted therapy or 
companion diagnostics for the treatment of this cancer.22 Very few studies on using such 
cells for theranostic assessment have been reported yet. 
2.2 Materials and Methods 
2.2.1 Study Design 
Nanosphere compatibility was assessed in human osteosarcoma U2OS cell line derived 
UTA-6 cells cultured in Dulbecco’s Modified Eagle’s medium (DMEM, Thermo) 
supplemented with 10% FBS, 100 units/mL penicillin and 100 μg/mL streptomycin at 
37°C with 5% CO2 under sterile conditions. Cells were grown until 80% confluent and 
then transferred into multi-well culture plates where they were kept for an additional 24 
hours to ensure complete adherence to the surface of the culture dish.  
The interaction of the conjugated GNs was assessed quantitatively with a plate reader and 
visually with a Nikon Ti Eclipse inverted microscope outfitted with an incubation 
chamber for live cell imaging. 2D brightfield and FITC-filtered 2D images and 3D z-
stack images were collected to visualize the depth of GNs interaction with cells. The 
microscope was focused at 150 μm, which pertained to the height of which the surface of 
the cells was clearly visible. 
Biocompatibility was assessed colorimetrically with a MTT cell viability Assay (Sigma- 
Aldrich) in triplicate incubated with 5, 10, 20, and 40 μg of GNs for 24 hours. 
2.2.2  Gelatin Nanosphere Synthesis 
GNs were synthesized from Type A gelatin derived from porcine skin (175 Bloom, 
Sigma-Aldrich) using a modified two-step desolvation method (Figure 2-1) described by 
Coester et al.23  1.25 g of gelatin was dissolved in 25 mL water under constant stirring 
and heating at 40°C. Once dissolved, 25 mL of acetone was added as a desolvating agent. 
The low molecular weight gelatin contained in the supernatant of the gelatin solution 
centrifuged at 5000 rpm for 15 minutes was discarded. The remaining gelatin was re-
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Figure 2-1. Two-step desolvation method of gelatin nanosphere (GNs) synthesis. 
Stabilization of GNs was achieved by crosslinking with glutaraldehyde. 
dissolved in 25 mL of deionized water acidified with hydrochloric acid (pH 2.5 - 3.0) 
under constant stirring and heating at 40°C. Gelatin was desolvated again by the 
dropwise addition of 75 mL of acetone under constant stirring and heating at 40°C. After 
10 minutes of stirring, 250 μL of a 25% glutaraldehyde solution was added to crosslink 
the gelatin at 40C. The produced nanoparticles were dried at 50°C in an oven. 
 
 
 
 
 
 
 
 
 
 
2.2.3 Functionalization of CdSe/ZnS Core Shell Quantum Dots 
Zinc sulfide capped cadmium selenium core-shell quantum dots (CdSe/ZnS) were 
synthesized from a modified method based on previous reports (Figure 2-2).24,25 First 
CdSe quantum dots (QDs) were synthesized. A selenium precursor solution was prepared 
by dissolving 0.79 g selenium (Se) in 10 mL of trioctyl phosphine (TOP). A cadmium 
(Cd) solution was prepared by dissolving 0.46 g cadmium acetate dissolved in 10 mL of 
TOP and heated to 100°C under argon for 1 hour. The Se precursor was then injected into 
the Cd solution and allowed to stay at 80°C. Meanwhile, 20 g of trioctyl phosphine oxide 
(TOPO), 10 g of hexyldecylamine (HDA), and 5 mL of TOP was heated to 120°C under 
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Figure 2-2. Synthesis scheme of CdSe/Zn/Cysteamine QDs. Organometallic synthesis of 
the CdSe QD core was subject to ZnS capping to form a core shell entity. Amine (-NH2) 
functionalization to render the QDs water-soluble and biocompatible was achieved 
through a thiol-exchange reaction with cysteamine hydrochloride. 
vacuum for 2- 3 hours. This mixture was further heated to 340°C under argon protection 
and the CdSe solution as injected. The produced CdSe QDs were stored in hexane. 
Following that, a ZnS shell was applied to the CdSe QD to reduce its cytotoxic effects. 4 
g of HDA, 8 g of TOPO were mixed at 180°C. 50 mg of CdSe QD dispersed in 2 mL of 
chloroform was added to the solution. Once the chloroform was pumped away, argon gas 
was introduced into reactor. A mixture of zinc acetate (54 mg), bis(trimethylsilyl)sulfide 
(0.05 mL) was dissolved in 1 mL each of TOP and oleylamine and injected dropwise into 
theQDs solution. The reaction was allowed to proceed for 1 hour at 180-185°C. 
CdSe/ZnS QDs were stored in hexane after centrifuging. In addition, cysteamine-
functionalized CdSe/ZnS QDs were further developed to be water-soluble and capable of 
conjugation with GNs.26 Briefly, CdSe/ZnS QDs were dispersed in a ratio of 20 mg of 
QDs per 3 mL of chloroform. Meanwhile, 100 mg of cysteamine hydrochloride was 
dissolved in 5 mL of deionized water. The solutions were combined and sonicated until 
the chloroform layer was clear. Free cysteamine was removed by reacting with 20 mM of 
2-mercaptoethanol. The cysteamine functionalized CdSe/ZnS/QDs were collected after a 
threefold centrifugation and redispersed in deionized water at 8000 rpm for 10 minutes. 
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Figure 2-3. Functionalization scheme of Gelatin Nanospheres. Exploitation of the 
functional groups present on GN surface allows for the hybridization of QDs and 
bioconjugation of anti-IgG through a serious of dehydration reactions. 
2.2.4 Bioconjugation of GNs with anti-human Immunoglobulin G 
Fab 
GNs were conjugated with anti-human immunoglobulin G (anti-IgG) Fab purchased from 
Sigma, Aldrich. The anti-IgG Fab contains the antigen binding site. 5 mg of GNs in1 mL 
borate buffer (pKa of 9.14 at 25°C) mixed with 20 μL of fluorescence FITC-tagged anti-
IgG Fab solution and stock anti-human IgG Fab (4 mg/mL), respectively. The sample 
was agitated gently for 2 hours. Conjugated GNs were collected through a 0.5 mL 100 
kDa cut-off centrifugal filter with deionized water. GNs modified with FITC-anti IgG 
Fab were used in comparison to GNs modified with anti-IgG Fab and QDs as shown in 
Figure 2-3. 
2.2.5 QDs incorporating with GNs 
 
 
 
 
 
 
 
 
 
 
 
In 1 mL of borate buffer, approximately 5mg of GNs with and without conjugation of 
anti-IgG Fab mixed with 13 μL of a 3.75 mg/mL solution of cysteamine modified 
CdSe/ZnS QDs following gentle agitation for 2 hours (Figure 2-3). GNs with and 
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without antibody-conjugation were further tagged by cysteamine modified CdSe/ZnS 
QDs. Samples were collected after a threefold centrifugation through a 10 kDa cut-off 
centrifugal filter and re-dispersed with deionized water. Centrifugation occurred at 7000 
rpm for 10 minutes. 
2.2.6 Materials Characterization 
Materials microstructure were investigated by a Philips CM-10 transmission electron 
microscope (TEM) operating at 100 kv and a high resolution TEM (JEOL 2010 F, 
operating at 200 kv). The diameter of the nanospheres were analyzed with ImageJ 
software (National Institutes of Health, USA) with an ANOVA and Kruskal-Wallis 
(p<0.0001). The Zeta (ζ) potential of the GNs was measured by Malvern Zetasizer 
3000HSA, and calculated as the mean of 5 individual measurements. In addition, the 
photoluminescence (PL) of fluorescent nanomaterials was investigated by a 
QuantaMaster™ 40 Spectrofluorometer (Photon Technology International Inc). 
2.2.7 Conjugation Efficiency 
Quantification of anti-IgG Fab Conjugated to GNs 
The amount of FITC-anti-IgG Fab conjugated to the 5 mg of GNs was determined by 
measuring the absorbance at 280 nm (A280nm) with a UV/Vis spectrophotometer 
(Agilent Technologies Cary 60) in triplicate. The protein concentration (M) of FITC-anti-
IgG Fab was measured using the formula provided by ThermoScientific. 
Equation 2-1 
𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑀)  =  
[𝐴280  −  (𝐴𝑚𝑎𝑥  𝑥 𝐶𝐹)]
𝜀
 𝑥 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 
Where Amax is the absorbance (A) of a dye solution measured at the wavelength 
maximum (λmax) for the dye molecule. The correction factor (CF) of 0.36 was obtained 
from the manufacturer of the FITC-anti-IgG Fab protein. The molar extinction coefficient 
of the anti-IgG Fab (ε) was taken to be approximately 210,000 M-1 cm-1.  
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Figure 2-4. Protein standard curve of anti-IgG Fab. Standard curve was used to 
determine the amount of unbound anti-IgG from the bioconjugation with GNs using a 
BCA assay kit. 
In the situation of the non-fluorescent anti-IgG Fab, the concentration of the non-
conjugated anti-IgG Fab collected from the filtrate was determined colorimetrically by a 
Thermo Scientific Micro BCA Protein Assay Kit relative to a standard curve (Figure 2-
4) generated from the anti-IgG stock solution (4 mg/mL). In short, the bicinchoninic acid 
was reduced by specific amino acids in an alkaline environment to form a water-soluble 
product of which its absorbance was measured at 560 nm. 
 
 
 
 
 
 
 
 
 
 
Ratio of QD to GNs with and without antibody conjugation 
Both UV absorbance intensity and fluorescence emission intensity (λex: 490nm) of 
produced QDs were measured as a function of the amount of modified QDs-GNs, 
respectively. The amount of QDs tagged onto the GNs with and without antibody 
bioconjugation were estimated based on the standard curves (Figure 2-5). 
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Figure 2-5. Standard curve of CdSe/ZnS/Cys QDs absorbance. The absorbance of the 
QDs-GNs was measured to determine the amount of QDs hybridized. 
 
 
 
 
 
 
 
 
 
 
2.2.8 Cell Viability 
24-hour cell viability of the functionalized GNs was assessed. Approximately 50,000 
cells were seeded into each well of a 24 well plate and cultivated overnight at 37°C. 
UTA-6 cells were incubated with 5, 10, 20, and 40 μg of samples for 24 hours at 37°C in 
triplicate. The cell media was aspirated and rinsed twice with sterile PBS to remove free 
nanoparticles. Each well was incubated with 200 μL of growth media and 50 μL of sterile 
0.5% MTT solution (0.5 mg MTT formazan powder/mL of deionized water) for 4 hours. 
The media was aspirated and wells were twice rinsed with sterile PBS. 150 μL of DMSO 
was added to each well to lyse the cells and to dissolve the tetrazolium salt. The 
absorbance of the plates was measured at 490 nm. 
2.2.9 Statistical Analysis 
In order to determine the statistical significance in size as a result of hybridization and 
bioconjugation with anti-IgG, we performed a One-Way analysis of variance (ANOVA) 
using GraphPad Prism (GraphPad Software Inc, La Jolla, CA, USA). Bioconjugation 
with FITC-anti-IgG and anti-IgG was assessed with a Mann Whitney t-test to indicate no 
significant difference in the bioconjugation amount. Furthermore, we compared the 
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Figure 2-6. TEM micrographs of 175 bloom GNs. A) GNs without modifications were 
determined to be 270 ± 50 nm. B) Hybrid GNs (i.e. QDs-GN-anti-IgG) were estimated to 
be 480 ± 50 nm in diameter. The QDs, as indicated by the red outlines, were visualized 
with TEM. A high-resolution inset of the CdSe/ZnS hybridized QDs is included. 
increase in cellular interaction between GNs-anti-IgG-FITC and QDs-GNs-anti-IgG with 
a t-test relative to the GNs-QDs signal. Cell viability was assessed with a Two-Way 
ANOVA to study the impact as a result of modification and concentration. All statistical 
analyses were assessed at the 95% confidence level. 
2.3 Results 
GNs with and without functionalization were characterized by using transmission 
electron microscope (TEM, Figure 2-6A). The average particle size of bare GNs is 
estimated at 270 ± 50 nm; whereas the average size of the hybrid fluorescent GNs 
conjugated with antibodies significantly increases up to 480 ± 50 nm. Moreover, high 
crystallized CdSe/ZnS QDS (5 ± 2 nm) sporadically surrounding the surface of the GNs 
was identified by the high resolution TEM (Figure 2-6B).  
 
 
 
 
 
 
 
 
 
 
To quantitatively study the bioconjugation of the hybrid GNs, we produced GNs with the 
conjugation of FITC labelled anti-IgG Fab (GN-anti-IgG-FITC) using the same method. 
The amount of FITC-labelled anti-IgG Fab bioconjugating onto GNs was determined by 
comparing with the standard curve of the fluorescence emission intensity of FITC as a 
function of the amount of FITC. Meanwhile, free anti-IgG Fab protein which are not 
conjugated to the GNs were quantitatively measured by a colorimetric assay with a 
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Thermo Scientific Micro BCA Protein Assay Kit. Taking the molecular weight of the 
antibody fragment to be 50 kDa (50,000 g/mol), it was estimated that 12.773 ± 0.695 μg 
of anti-IgG Fab has been conjugated onto 1 mg of FITC tagged GNs (Table 2-1). 
Analysis indicated no significant difference (p = 0.2000) in the amount of anti-IgG with 
and without FITC-tagging bioconjugated onto GNs. It suggests the bioconjugation of 
anti-IgG onto GNs is successful. Table 2-1 also shows the calculated amount of anti-IgG 
Fab conjugated to the QDs tagged GNs (1mg) is 12.167 ± 0.216 μg.  
In addition, the amount of QDs hybridized onto the GNs with/without anti-IgG Fab was 
also estimated by comparing the standard curves. It is estimated that 0.0404 ± 0.003 μg 
and 0.0432 ± 0.005 μg of QDs are covalently bound onto the surface of 1 mg of GNs 
with/without anti-IgG Fab, respectively (Table 2-1). 
Table 2-1. Hybridization and conjugation quantification 
Hybrid 
Nanospheres 
Amount of anti-IgG Fab (µg) 
conjugated on GNs (1 mg) 
Amount of QDs (µg) tagged 
on GNs (1 mg) 
QDs-GN ---- 0.0432 ± 0.005 
GN-anti-IgG-FITC 12.733 ± 0.0491 ---- 
QDs-GN-anti-IgG 12.167 ± 0.216 0.0404 ± 0.003 
*Significance of difference (p = 0.2000) determined by one-way analysis of variance. 
Bioconjugation of FITC-tagged anti-IgG on to GNs (GN-anti-IgG-FITC) was used as a 
reference for the QDs-GN-anti-IgG model to ensure the hybridization of QDs did not 
affect the anti-IgG bioconjugation. 
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Figure 2-7. Determination of the interaction between functionalized GNs and UTA-6 
cells. A) Photoluminescence spectra of modified QDs. B) Photluminescence spectra of 
the QDs-GNs and QDs-GNs-anti-IgG (Fab) interaction. C) Relative interaction of GNs-
anti-IgG-FITC (Fab) and QDs-GNs- anti-IgG (Fab) normalized to QDs-GNs. D) 
Fluorescent image of cells treated with QDs-GNs. E) 3D z-stack of internalized QDs-
GNs. F) Fluorescent image of cells treated with QDs-GNs-anti-IgG. G) 3D z-stack of 
internalized QDs-GNs-anti-IgG. 
*location of the nanospheres are outlined in red. 
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Figure 2-7A shows the emission wavelength (λem) of CdSe QDs centered at 667 nm 
measured by a QuantaMaster™ 40 Spectrofluorometer. The 13 nm blue shift of the λem is 
observed by the CdSe/ZnS QDs (λem = 654 nm). Furthermore, there is no observed shift 
in fluorescent emission between QDs-GNs and QDs-GN-anti- IgG Fab (Figure 2-7B). It 
further indicates that the conjugations between antibody to GN and QDs to GN are 
independent due to the two different functional groups (-OH and –COOH) on a single 
GN.  
On the other hand, the interaction of the conjugated hybrid GNs and UTA-6 cells was 
assessed visually with a Nikon Ti Eclipse inverted microscope outfitted with an 
incubation chamber for live cell imaging. A fluorescence spectrometry affiliated with the 
microscope was applied to quantitatively study the interaction. The GNs conjugated with 
anti-IgG Fab associate significantly more with the cells than those without (p = 0.0023). 
When normalized against QDs-GNs, the hybrid GNs conjugated with antibody fragments 
and QDs exhibit insignificant difference in interaction that their fluorescent tagged 
counterpart (Figure 2-7C) when statistically assessed (p=0.3770). This result further 
confirms with our quantitative analysis of the amount of antibody fragment conjugated on 
GNs.  
The 2D images of the hybridized QDs-GNs (Figure 2-7D) and antibody fragment-
bioconjugated QDs-GNs (Figure 2-7F) indicate the interaction between cells and GNs 
with and without antibody conjugation. Upon closer examination, we obtain more details 
through 3D z-stacking images on hybrid GNs associated on the cell surface (GNs-QDs, 
Figure 2-7E) and cellular internalization (QDs-GNs-anti-IgG, Figure 2-7G). The 
majority of the fluorescence signals originating below the 150 μm mark, suggests 
nanosphere internalization. The statistical analysis shows the anti-IgG Fab bioconjugated 
QDs-GNs is able to gain 50% higher in cellular uptake and internalization by UTA-6 
osteosarcoma cells than its nonbioconjugated counterpart. 
The relative cell (UTA-6 cell line) viability after incubation for 24 hours with various 
amounts (5, 10, 20, and 40 μg) of nanospheres decreased with increasing nanosphere 
amount. In Figure 2-8, cell viability decreases with increasing nanosphere concentration. 
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Figure 2-8. Relative viability of osteosarcoma cells incubated with various 
concentrations of functionalized GNs for 24 hours. Viability was assessed in triplicate. 
The relative cell viability remained at or above 80% even when incubated with 40 μg of 
nanospheres. A two-way ANOVA indicated no significant difference (p=0.8074) in cell 
viability between the different samples as result of concentration changes. 
 
 
 
 
 
 
 
 
 
2.4 Discussion 
Our GNs model provides insight into the impact of modifications on the potential for 
GNs to be utilized in a theranostic fashion for in vivo fluorescent imaging and enhanced 
cellular interaction for prospective therapeutic delivery. 
Several groups have already studied the in vitro or in vivo release profile of drug-
encapsulated in GNs and demonstrated sustained release. Our group and that of Arbab et 
al. demonstrated Fickian diffusion, where drug diffusion and polymer morphology can 
control the overall rate of drug release, for in vitro applications of GNs with sustained 
release of protein for up to 7 days.27,28 In vivo applications demonstrate a non-Fickian 
sustained release profile of up to 24 hours as a result of degradation and erosion in a 
biological environment.29,30  
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Applications of GNs for therapeutic applications require targeted selectivity to ensure 
accurate delivery to the site of interest to release its therapeutic payload. Covalent 
bonding is optimal to ensure the protein target or antibody of choice is “superglued” to 
the GN surface. With the ζ potential of GNs is measured at 24.1 ± 0.4mV, i.e. uncharged 
surface. In the other words, both functional groups, i.e. (-COOH) and (-NH2), are 
available on the surface of GNs for post synthesis modifications. 
Our modification analysis suggests the QDs covalently bind into the GNs through the 
reaction between the amine groups of cysteamine modified on the QDs and the 
carboxylic groups on the exterior of the GNs (Table 1). Due to the covalent bonding, the 
hybridization performed post nanoparticle synthesis will not affect the drug loading 
process nor contribute to the release of QDs as seen in the method described by Chen et 
al.31 In addition, the intra-particle space for drug encapsulation would be retained with 
the hybridization method, which could be suitable for the nanoprecipitation method. For 
instance, Narayanan et al.32 load the anti-inflammatory drug Ibuprofen-sodium 
successfully with an entrapment efficiency of ~70%. 
The insignificant difference in the quantity of QDs on GNs with/without the 
bioconjugation of anti-IgG Fab suggest the QDs were hybridized in a stable manner onto 
the GNs. In addition, the quantitative analysis suggests neither surface modification 
procedures interfere with the other, indicating the molecules reacted non-competitively 
with the functional groups on the GNs surface. As such, a one-pot reaction to both 
hybridization and bioconjugation of the GNs is possible (Figure 2-3). 
The fluorescent component of the QDs is detrimental to the detection of the GNs. We 
observed an obvious blue shift of the cysteamine modified CdSe/ZnS QDs (λem =647 
nm) as shown in Figure 2-7A,B, which could be caused by the positively charged surface 
of the cysteamine modified QDs.33 It may result from the band-to-band recombination in 
the nanocrystal core.13  After conjugating the modified CdSe/ZnS QDs onto the GNs 
through covalent bond, the λem of the hybrid fluorescent nanospheres is around 652 nm, 
similar to the emission of CdSe/ZnS QDs. As shown in Figure 2-7 through live cell 
imaging (D, F) and z-stack imaging (E, G), we were successful in localizing the GNs 
54 
 
 
with respect to the cell. We observed an increase in cell surface interaction and 
internalization as a direct result of the anti-IgG conjugation (Figure 2-7C).  
Our in vivo investigation of the GNs’ interaction with osteosarcoma cells demonstrated 
potential for targeted therapeutic delivery. It is noted the relative cell viability of human 
fibroblasts treated with 10 μg/mL bare GNs is about 100% viability in comparison to our 
observed ~80% at 40 μg/mL (Figure 2-8). The difference in cell viability could be 
attributed to the size distribution of our model and the functional groups involved in the 
modification processes. Gupta et al. demonstrated their GNs (37 ± 0.84 nm) produced via 
microemulsion affected cellular proliferation/viability.6 Through immunostaining, it was 
determined phagocytosed nanoparticles caused vacuole formation within the cell body 
resulting in a disrupted cytoskeleton. The F-actin was organized in an anisotropic fashion 
with poorly developed filament bundles. Tubulin was observed to be disrupted and 
dispersed. Together, these disruptions inhibited cytokinesis. From our observed 
internalization, we concluded the size of our nanoparticle in the same sense disrupted the 
organization of these important fibres by filling much of the cell area thus compromising 
cytokinesis. The cellular membrane was observed to remain intact in our case. 
Another cause of our relatively decreased viability of hybrid GNs could be attributed to 
cell cycle arrest caused by amino-modified QDs. As shown by Kim et al.,34 the amino-
modified polystyrene nanoparticles interfered with the cell cycle as cell numbers did not 
increase over longer incubation times. They observed the accumulation of cells between 
the transition points G1/S and G2/M phases of mitosis. It was unlikely the amino-
modified QDs hybridized onto GNs arrested mitosis simply due to the amino groups, 
though it may have contributed. The size of our nanoparticle would likely have been the 
factor in inhibiting cytokinesis. 
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CHAPTER 3  
To quantitatively assess the effects of modification strategies of our hybridized drug 
delivery model composed of a gelatin nanoparticle drug reservoir and CdSe QDs 
modified with a non-cell specific targeting antibody anti-human immunoglobulin G 
(IgG). The goal was to assess the cytotoxic effects on U20S human osteosarcoma cell 
derived UTA-6 cells as a direct result of modification order: i) QDs first followed by 
IgG; or ii) IgG first followed by QDs. 
The contents of this chapter were previously published in the Journal of Biomaterials 
Applications: WH. Tse, L. Gyenis, DW. Litchfield, and J. Zhang. Cellular interaction 
influenced by surface modification strategies of gelatin-based nanoparticles. Journal of 
Biomaterials Applications. 2017: 31(7); 1087- 1096. doi: 10.1177/0885328216684651 
3 CELLULAR INTERACTION INFLUENCED BY 
SURFACE MODIFICATION STRATEGIES OF 
GELATIN-BASED NANOPARTICLES 
3.1 Introduction 
Therapeutic advantages of using gelatin as a drug carrier include biodegradability, 
biocompatibility, and low toxicity due from its animal origin.1,2 In its denatured form, 
gelatin has a long history in the clinical setting as a stabilizer in protein formulations and 
vaccines.3 The gelatin backbone contains amino acid sequences such as Arg-Gly-Asp that 
can influence cell adhesion, which are not found in polymers.3 Furthermore, from an 
engineering standpoint, gelatin’s low cost and the presence of functional groups (–NH2 
and –COOH) allow for easy crosslinking to add stability and chemical modifications in 
its nanoparticle form.4 Efforts to develop gelatin as a theranostic agent for concurrent 
application in diagnostics and therapeutics, have proved successful in in vitro and animal 
models.5,6 In the past, attempts have been made by loading fluorophores or synthetic dyes 
into nanoparticles for simultaneous cell-tracking and drug-delivery.7–9 However, due to 
photobleaching, alternatives such as semiconductor quantum dots (QDs) are required.8,10 
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QDs with a diameter in the range of tens of nm exhibit quantum confinement properties 
resulting in fluorescence under optical stimulation. Its emission peak is narrower than 
that of conventional dyes and can be tuned to emit at different frequencies depending on 
the particle’s diameter.11 Generally, these particles are thermally decomposed grown from 
heavy metals that are highly toxic.12 Encapsulation methods have been developed to 
minimize toxicity and enhance its optical properties.13,14 Cadmium-based QDs were one 
of the first types to be made and used in biological and biomedical research. 
Advancements in this area have led to the incorporation into drug delivery vehicles for 
optical confirmation. The results show promise for inclusion into a candidate model for 
targeted drug delivery. 
One aspect of functionalization for targeted drug delivery is to reduce the therapeutic 
load through localized delivery. The premise is particles-modified with ligands and other 
cell-specific entities will circulate and associate directly with the tissue of choice and 
exert its therapeutic effects locally.15 Compared to more traditional drug-delivery 
methods of intravenous infusions, injections, and oral capsules, the nanocarriers carry a 
smaller therapeutic load therefore minimizing adverse effects.16,17 
Many approaches using various material compositions and surface modifications have 
been developed to enhance cellular interaction, minimize size, and more importantly 
increase cellular internalization of nanoparticles. Others have looked into the in vivo 
imaging properties and drug-delivery capabilities of nanoparticles.18–22 Such instances 
include the addition of polyethylene glycol (PEG) polymers to increase circulation time 
and inhibit opsonization.23 Through the process of PEGylation, coupling of PEG, 
nanoparticles can exhibit properties such as suppression of protein adsorption, increase in 
hydrophilicity, and decreased interaction with serum components to name a few that 
contribute to its lowered opsonization.24 As demonstrated by Madan et al.,25 PEGylated 
gelatin nanoparticles (GNPs) introduced in murine models show the improved 
bioavailability compared to the non-PEGylated GNP nanoparticles, which results in a 
longer circulation time. PEGylation prevents the formation of a protein corona which 
triggers opsonization, the elimination of foreign by endocytosis, through steric 
inhibition.25,26 
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The recombination of current technologies and reengineering may provide a suitable 
theranostic nanoparticle capable of simultaneous drug encapsulation and delivery, 
enhanced cellular association, and optical properties for visual confirmation of cellular 
association. Our model hybridizes organic, biocompatible GNPs with inorganic, 
semiconductive QDs to provide localized optically-identifiable drug-release vehicles for 
the purpose of minimizing disruptions to cellular mechanisms. The incorporation of 
targeting ligands directed towards extracellular surface association may prevent negative 
effects such as apoptosis or occupying the intracellular matrix to cause disruptions to 
normal cellular function. The functionalization strategies of the model carrier and its 
cellular interaction will aid to further understand the parameters of developing 
personalized medicine. 
3.2 Materials and Methods 
3.2.1 Study Design 
Nanoparticle compatibility made from 90 bloom gelatin functionalized via 2 different 
pathways was assessed on human osteosarcoma U2OS cell derived UTA-6 cells27 
cultured in Dulbecco’s Modified Eagle’s medium (DMEM, Thermo Fisher Scientific) 
supplemented with 10% FBS, 100 units/mL penicillin and 100 μg/mL streptomycin at 37 
°C with 5% CO2 under sterile conditions. Cells were grown until 80% confluent and then 
transferred into multi-well culture plates where they were kept for an additional 24 hours 
to ensure complete adherence to the surface of the culture dish. 
The effect as a result of modifications: i) QDs first followed by anti-IgG or ii) anti-IgG 
first followed by QDs, was assessed colormetrically with a MTT cell viability assay. The 
interaction of the conjugated GNPs was visually with a Nikon Ti Eclipse inverted 
microscope outfitted with an incubation chamber for live cell imaging. 2D brightfield and 
FITC-filtered 2D images and 3D z-stack images were collected to visualize the depth of 
GNPs interaction with cells. The microscope was focused at 250 μm, which pertained to 
the height of which the surface of the cells was clearly visible. 
 
62 
 
 
Figure 3-1. Two-step desolvation method of gelatin nanoparticle (GNP) synthesis. 
Stabilization of GNPs was achieved by crosslinking with glutaraldehyde. 
3.2.2 Gelatin Synthesis 
GNPs were synthesized according to the two-step desolvation method by Coester et al.28 
from 90 bloom Type A gelatin from porcine skin (Figure 3-1). In short, 2.5 g of gelatin 
was dissolved in 50mL of 18.2 MΩ•cm water under constant stirring at 40C for 15 min. 
In all, 50mL of acetone was added to desolvate the gelatin for 5 min, which was then 
collected and centrifuged at 5000 G for 15 min. The supernatant containing lower 
molecular weight gelatin was discarded. 
The gelatin was then redissolved in 50mL of acidified (pH 2.5) deionized water at 40 C 
under constant stirring. A total of 150mL of acetone was added drop-wise to desolvate 
the gelatin. The gelatin was crosslinked with 500 mL of glutaraldehyde (25% solution) 
and allowed to stir at 40 C for 30 min. The GNP was thrice collected and centrifuged at 
6000 r/ min for 15 min thrice with ethanol. GNPs were redispersed in ethanol and dried.  
 
 
 
 
 
 
 
 
 
 
63 
 
 
Figure 3-2. Fluorescence Change of CdSe QD with Subsequent Modifications. 
Modification of the CdSe with zinc sulfide (ZnS) and cysteamine hydrochloride (Cys) 
blue shifted the QD. As a result of the introduction of amine groups, a marked decrease in 
fluorescent intensity is observed. 
3.2.3 CdSe/ZnS Cysteamine Modified Quantum Dots 
Here we produced CdSe/ZnS QDs through a chemical method described by Duong and 
Rhee.29 These QDs were further functionalized with cysteamine (HSCH2CH2NH2) 
through a thiol exchange method with primary amine groups to be water-soluble and 
primed for GNP hybridization.30 The resultant sample CdSe/ZnS/Cys QDs from here on 
simply known as QDs was hybridized onto the surface of the GNP. In addition, the 
photoluminescence of the fluorescent QDs was investigated by a QuantaMaster™ 40 
Spectrofluorometer (Photon Technology International Inc) is reported in Figure 3-2. 
 
 
 
 
 
 
 
 
 
3.2.4 PEG-epoxide Synthesis 
As per the method of Kaul and Amiji31 for PEG-epoxide synthesis, monomethoxy-
poly(ethylene glycol) (PEG, MW: 5000 g/mol) was converted into an epoxide for 
conjugation. A 5-mM solution of monomethoxy- PEG in N,N-dimethylformamide 
containing 1% (w/v) of triethanolamine was heated at 40 C for 4 h with constant stirring 
then cooled to room temperature. To this solution, 5:1 molar ratio of epichlorhydrin to 
PEG was added and stirred overnight under reflux conditions. The epoxide derivative 
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was precipitated in cold diethyl ether. The PEG-epoxide was washed thrice with diethyl 
ether and dried in vacuum. 
3.2.5 Functionalization Strategy 
The base GNP model was modified via two paths; Path A – QD first followed by anti-
IgG and Path B – anti-IgG first followed by QD (Figure 3-3). The model utilizes a buffer 
to form covalent bonds through a dehydration reaction between carboxylic groups (-
COOH) and primary amine groups (-NH2) to form an amide bond (-CONH-). 
Approximately 50 mg of GNP was reacted in 5mL of pH 8.5 borate buffer with 50 mg of 
CdSe/ZnS/Cys QDs or 200 mL of a stock non-fluorescently tagged antihuman IgG Fab (4 
mg/mL) solution for 2 h under constant agitation. The hybridized GNP was purified 
through a 100 kDa Eppendorf centrifugal tube filter thrice at 5000 r/min for 5 min with 
ethanol. Collected modified GNP was resuspended in the buffer to conjugate the 
remaining component or resuspended in ethanol for storage.  
The model functionalized by Path A or Path B was then capped with PEG. In all, 25 mg 
of GNP-QD/anti-IgG or GNP-anti-IgG/QD was suspended in 5mL of the aforementioned 
buffer along with 10 mg of PEG-epoxide under constant agitation to bioconjugate 
overnight. PEG capped GNP was purified through a 100-kDa Eppendorf centrifugal tube 
filter thrice at 5000 r/min for 5 min with ethanol. The PEG modified particles were 
redispersed in ethanol and dried. 
*Post-synthesis functionalizations are listed in the order of modification in the sample 
designation. (ex: GNP-QD-anti-IgG; GNPs modified with QDs first followed by anti-
IgG) 
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Figure 3-3. Schematic of GNP modifications. Modification paths of 90 bloom-based 
GNP: Path A - Cadmium Selenium Cysteamine modified Quantum Dots (CdSe/ZnS/Cys 
QD) first; Path B - anti-human Immunoglobulin G Fab (anti-IgG) first. The order of 
modification exposes different groups on the surface for subsequent modifications. 
Modifications rely on the formation of amide (-CONH-) bonds to covalently stabilized 
the constituents. *constituents are listed in order of modification. 
 
 
 
 
 
 
 
 
 
 
3.2.6 Confirmation of QD, anti-IgG and PEG modifications 
A colorimetric assay was performed to confirm the successful incorporation of anti-IgG, 
QD, and PEG onto the surface of the GNP. In triplicate, 5 mg of the various modified and 
non-modified GNP samples suspended in 100 mL of deionized water was incubated with 
5 mL of a 1 M solution of 2,4,6-trinitrobenzemesulfonic acid (TNBS). Samples were left 
at room temperature for 2 h to react the primary amine groups with TNBS. The 
absorbance measured at 405 nm was normalized to the measured non-modified GNP. 
Meanwhile, transmission electron microscopy (TEM, Philips CM-10 operated at 80 kV) 
was carried out to characterize the particle size of hybrid GNP with/without 
modifications.   
3.2.7 Materials Characterization 
Materials microstructure were investigated by a Philips CM-10 transmission electron 
microscope (TEM) operating at 100 kv and a high resolution TEM (JEOL 2010 F, 
operating at 200 kv). The diameter of the nanoparticles were analyzed with ImageJ 
software (National Institutes of Health, USA) with an ANOVA and Kruskal-Wallis (p < 
0.0001).  
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Figure 3-4. Standard Curves. A) Fluorescence intensity of QD. B) Absorbance of anti-IgG. 
The fluorescent standard curve was used to determine the amount of QD hybridized onto the 
GNP surface. The absorbance aided in determining the amount of anti-IgG remaining after 
the bioconjugation as a means to back calculate the amount that was bioconjugated. 
3.2.8 Quantification of QD and anti-IgG 
Quantification of QD 
The amount of QDs conjugated to the GNP and GNP anti-IgG was determined by 
measuring the absorbance at 490 nm in triplicate. The measured value was compared to a 
four-point standard curve to determine the amount of QDs on the functionalized GNP 
(Figure 3-4A). 
Quantification of anti-IgG 
Confirmation of anti-IgG bioconjugation onto the surface was confirmed measuring the 
residual anti-IgG content not conjugated to the GNP. The filtrate collected from the 
centrifugation process contained the remainder of the anti-IgG protein not conjugated to 
the GNP. The protein concentration of this solution was determined colorimetrically with 
a Thermo Scientific Micro BCA Protein Assay Kit using the anti-IgG stock solution to 
generate a four-point standard curve (Figure 3-4B). In short, the bicinchoninic acid 
(BCA) can be reduced by specific amino acids in an alkaline environment to form a 
water-soluble product, which has a typical absorbance at 560 nm. 
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3.2.9 Biocompatibility 
Cell Viability 
24-hour cell viability of the functionalized GNPs was assessed. Approximately 50, 000 
cells were seeded into each well of a 24 well plate and cultivated overnight at 37 °C. 
UTA-6 cells were incubated with 5, 10, 20, and 40 μg of samples functionalized with 
QDs and anti-IgG with/without PEG for 24 hours at 37 °C in triplicate. The cell media 
was aspirated and rinsed twice with sterile PBS to remove free nanoparticles. Each well 
was incubated with 200 μL of growth media and 50 μL of sterile 0.5% MTT solution (0.5 
mg MTT formazan powder/mL of deionized water) for 4 hours. The media was aspirated 
and wells were twice rinsed with sterile PBS. 150 μL of DMSO was added to each well 
to lyse the cells and to dissolve the tetrazolium salt. The absorbance of the plates was 
measured at 490 nm. 
Cellular Interaction 
The interaction of the conjugated GNP was assessed visually with a Nikon Ti Eclipse 
inverted microscope outfitted with an incubation chamber for live cell imaging where 
cells were incubated at 37C in 5% CO2. Brightfield and FITC images of the cells were 
collected in 2D and 3D z-stack to visualize the depth of GNP interaction with cells. 
Specificity of the conjugated GNP interaction with UTA-6 cells was assessed in 24-well 
plates; 125,000 cells were transferred into each well of a 24-well plate and incubated 
overnight. In triplicate, 100 mg of each type of fluorescently labeled GNP was incubated 
with cells for 30 min at 37 C. After this incubation, the cells were rinsed twice with 
sterile PBS to remove free particles. Wells were made up to 400 mL with sterile PBS and 
excited at 490 nm. 
3.2.10 Statistical Analysis 
In order to determine the statistical significance in size as a result of hybridization and 
bioconjugation with anti-IgG, QDs, and PEG, we performed a One-Way analysis of 
variance (ANOVA) using GraphPad Prism (GraphPad Software Inc, La Jolla, CA, USA). 
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Bioconjugation of QDs and anti-IgG was assessed a t-test, to assess a potential difference 
in the bioconjugation amount as a result of functionalization pathway. Furthermore, we 
assessed the cell viability of GNPs functionalized wit QDs, anti-IgG, and PEG with a 
Two-way ANOVA to study the impact of modification order and concentration. Cell 
viability was assessed with a Two-Way ANOVA to study the impact as a result of 
modification and concentration. Difference in amine groups to confirm functionalization 
assessed with a TNBS assay was statistically compared with a one-way ANOVA test. All 
statically analyses was assessed at the 95% confidence level. 
3.3 Results 
Our research on 90 bloom-based GNP emphasizes the physical characterization and 
cellular interaction of functionalization with CdSe/ZnS/Cys QDs, anti-human IgG Fab, 
and PEG. GNP base modification with QD and anti-IgG was characterized using TEM. 
The diameters of the GNPS calculated with ImageJ are presented in Figure 3-5B along 
with a TEM micrograph of the hybridized QD. Highly crystallized CdSe/ZnS QDs (5  2 
nm) characterized by high-resolution TEM (Figure 3-5A; inset) was found to be 
hybridized sporadically along the surface of the nanoparticles. The average size of bare 
GNP is estimated to be 167  43 nm. With base modifications of QDs (180  37 nm) and 
anti-IgG, a Kruskal-Wallis ANOVA analysis suggested the anti-IgG is the cause of the 
significant size increase (p<0.0001), resulting in an increase to 227  50 nm.  
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Figure 3-5. Microstructures of hybrid nanoparticles. A) TEM micrograph of hybrid 
nanoparticles GNP-QD is shown with clusters of hybridized QDs on the surface. B) 
Diameters of GNP indicate a significant increase with the bioconjugation of anti-IgG Fab 
from 167  43 nm to 227  50 nm (p < 0.0001). The same is observed when hybridized 
with CdSe/ZnS/Cys QD (180  37 nm). 
 
  
 
 
 
 
 
 
 
 
GNP modified by Path A (QD first) and Path B (anti-IgG first), respectively, with free 
primary amine groups was capped with PEG to increase biocompatibility. A significant 
difference (p < 0.05) in size between the two paths is observed as shown in Figure 3-6. 
The average particle size of GNP-QD/anti-IgG without and with PEG modification 
produced through Path A is estimated at 246  68nm and 264  79 nm; whereas the 
average particles size of the hybrid GNPS without and with PEG modification produced 
through Path B is reduced to 213  47nm and 224  46 nm. 
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Figure 3-6. Average particle size of functionalized nanoparticles via Paths A and B. 
Particles modified via Path B (anti-IgG first) demonstrated a significantly smaller 
diameter in comparison to its respective counterpart when modified via Path A (QD first) 
with p < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
A TNBS assay performed was able to simultaneously confirm the successful Paths A and 
B modifications of the individual components; anti-IgG, QD, and PEG. The change in 
free primary amine groups was normalized to bare GNP. Increases and decreases in the 
relative change confirmed the successful hybridization of QD, bioconjugation of anti-
IgG, and PEGylation. Shown in Figure 3-7, the TNBS assay was able to detect the 
minute changes in free primary amine groups relative to unmodified GNP as constituents 
were bonded to the model. Figure 3-7B (p = 0.0439) demonstrated and increase in amine 
groups as a result of the QD hybridization. No significant changes in free primary amine 
groups was observed (p = 0.0508) between modification with anti-IgG + QD versus anti-
IgG + QD + PEG. Table 1 summarizes the effect of modification order on the amount of 
constituents that can be hybridized or conjugated onto the surface of GNP. T-test analysis 
on the order of modification, Path A or Path B, does not significantly impact the amount 
of anti-IgG (p = 0.1000) or QD (p = 0.0727) able to be amalgamated to the GNP surface. 
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Figure 3-7. Change of free primary amine groups in GNP with subsequent modifications 
relative to unmodified GNP. A) Relative change after modification by Path A. 
Conjugation of PEG significantly reduces the amount of amine groups found on the 
surface (p = 0.0439). B) Path B changes demonstrated the QDs add a significant amount 
of amine groups (p = 0.0439) but is later reduced by the addition of PEG. 
It is noted that the results of a t-test analysis suggests no significant difference in 
conjugation amounts between the two paths of modification.  
 
 
 
 
 
 
 
 
 
 
 
Table 3-1. Impact of modification order on functionalization. 
Modification Path A Path B p Value 
Anti-IgG (μg/mg GNP) 6.33  0.04 7.06  0.02 0.1000 
QD (μg/μg GNP) 0.81  0.34 1.03  0.003 0.0727 
  
The corresponding cellular interaction and internalization of the GNPs modified via Path 
A and B were observed with a Nikon inverted microscope outfitted for live cell imaging. 
From Figure 3-8, we are able to visualize the interaction of bare GNP, GNP-QD/anti-
IgG, and GNP-QD/anti-IgG/PEG with the UTA-6 cells. With the focus set to 250 mm, 
we visualized the internalization and surface association more clearly with lower 
fluorescence intensity. Of those visible internalized GNP, Figure 3-8E indicates more of 
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Figure 3-8. Interaction of Path A modified GNP with UTA-6 cells. A) Brightfield of bare 
GNP. B and C) GNP-QD/anti-IgG fluorescence and z-stack, respectively. D and E) GNP-
QD/anti-IGIG/PEG's corresponding overlay and z-stack, respectively. Functionalized 
GNPs exhibit increased cellular interaction and bright fluorescence that is optically 
trackable. Nanoparticles are outlined in red. 
the PEG modified GNP accumulates within or near the surface of the UTA-6 cells 
compared to those without PEG, Figure 3-8C. Visual confirmation suggests more 
functionalized GNPs (Figure 3-8B and D) interact with UTA-6 cells in comparison to 
the bare GNP (Figure 3-8A). Similar results can be observed with GNP modified by Path 
B (Figure 3-9). Respective nanoparticles are outlined in red.  
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Figure 3-9. Cellular Interaction of GNP-anti-Ig/GQD and GNP-anti-IgG/QD/PEG with 
UTA-6 cells. Internalization and surface association is also observed in the fluorescent 
and brightfield overlay of A) GNP-anti-IgG/QD and B) GNP-anti-IgG/QD/PEG. 
Respective z-stacks are seen in B) and D). Taking 250 µm as the cell surface, all 
fluorescent signals detected below it were considered internalized. Nanoparticles are 
outlined in red. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The effect of modification strategies on cellular viability was assessed with an 
MTT assay, to determine the cell viability in triplicate of 25,000 UTA-6 cells treated with 
various amounts of modified and unmodified GNPS: 5, 10, and 20 mg for 24 h. Shown in 
Figure 3-10 are the relative cell viability results of GNP modified with anti-IgG and QD. 
The relative viability was calculated by normalizing the results to the absorbance of 
untreated UTA-6 cells. A two-way ANOVA of the relative viability is dependent on both 
sample type and sample amount. In comparison to the non-modified GNP, both the GNP-
QD/anti-IgG and GNP-anti-IgG/QD exhibit a significant difference (p < 0.0001) with a 
negative correlation with increasing amounts of sample. Furthermore, in comparing the 
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Figure 3-10. Average cell viability of functionalized GNP. Bare GNP demonstrated 
significant difference in viability with modified GNP (p < 0.001). A decline in viability is 
observed with increasing concentration. At a concentration of 40 μg, there was an 
observed significant difference between GNP-QD/anti-IgG and GNP-anti-IgG/QD (p < 
0.01), with GNP-anti-IgG/QD at a greater rate of decline. 
functionalized samples, anti-IgG/QD samples exhibited a significant decrease (p < 0.05) 
in overall viability than QD/anti-IgG functionalized samples. 
 
 
 
 
 
 
 
 
 
The GNP-QD/anti-IgG sample, shown in Figure 3-11A, exhibited a significantly 
higher relative cellular viability compared to its PEGylated counterpart (GNP-QD/ anti-
IgG/PEG) with p = 0.0034. A two-way ANOVA analysis confirmed the PEG negatively 
affected the relative cell viability (p = 0.0034). The opposite was observed for samples 
modified by Path B (Figure 3-11B; p = 0.0019), where PEG aided in improving cellular 
viability. 
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Figure 3-11. Relative cellular viability of the GNP model capped with PEG after 24-h 
incubation. A) Relative viability of PEG-capped GNP modified by Path A. In 
comparison to its PEG-capped counterpart, the GNP-QD/anti-IgG has a significantly 
higher relative viability (p = 0.0034) at 5 and 40 µg. The PEG modification decreased the 
relative viability consistently with increasing sample amount. B) Conversely, PEG 
mitigated the decrease in viability seen in GNP-anti-IgG/QD samples. PEG modification 
significantly increased the relative cell viability (p = 0.0019) at 5 and 40 µg. 
 
 
 
 
 
 
 
 
 
3.4 Discussion 
Our GNP model provides insight into the impact of modification strategy on the potential 
for GNPs to be utilized in a theranostic fashion for in vivo fluorescent imaging and 
enhanced cellular interaction.  
From our investigation into the functionalization of the GNPs with anti-IgG, QDs, and 
PEG, it is evident that the source of the increase of amine groups is due to the addition of 
QDs as seen in Figure 3-7B; as to be expected due to the thiol exchange from the 
cysteamine onto the QDs. From both figures, it is evident the PEG and the anti-IgG are 
conjugating with primary amine groups, hence the visible decrease in relative amine 
presence. Furthermore, a comparison between relatively similar modifications, anti-IgG + 
QD and anti-IgG + QD + PEG, evidenced no significant change in free primary amine 
groups (p = 0.0508). The functionalization is dependent on the formation of amide bonds 
which directly impacts the amount of QD or anti-IgG capable of being conjugated onto 
the GNP surface.  
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Fundamentally, the GNP modified by either paths exhibited similar physical 
characteristics (Figure 3-3). Modifications despite order did not significantly impact the 
amount of QD or anti-IgG able to be hybridized or bioconjugated, respectively (Table 1), 
while there was a significant difference in size (p < 0.05) respective to Paths A and B 
modified with PEG (Figure 3-6). The main impact on size was the addition of anti-IgG 
(Figure 3-5). An enquiry into cellular interaction reveals differences in the interaction 
based on modification strategies. 
Due to the physical chemical nature of the GNP, an accurate measure of the number of 
particles interacting with the UTA-6 cells could not be quantified. Not all particles could 
be tagged with a significant amount of QDs to generate a detectable signal (Figure 3-8). 
However, from the live cell imaging, a distinction between the cellular interaction 
between functionalized and bare GNP could be clearly observed. GNP modified with 
anti-IgG exhibited enhanced interaction properties compared to non-modified GNPs.  
Figure 3-8 and 3-9 suggests the addition of PEG aids the GNP to be internalized more 
readily than those without.  
Cellular toxicity is a factor to be considered in all therapeutic settings. A suitable 
nanocarrier must minimize the impact to healthy cells while executing its function. One 
primary goal of our nanocarrier was to maintain good cellular viability in efforts to 
manage the symptoms of incurable diseases and delay progression in a therapeutic 
capacity. The results indicate functionalization strategy: (a) type and (b) order of 
modification are major factors in overall viability.  
The size of a nanoparticle can determine its feasibility to be internalized by a cell. As 
seen in the z-stacks in Figure 3-8 and 3-9, we observed functionalized nanospheres with 
and without PEG to be both associated onto the surface of the UTA-6 cells and 
internalized based on the location of the fluorescent signal. The result of internalization 
of small particles through endocytosis, though the internalization mechanism is still 
unclear, can be detrimental to the overall health of cells.32,33  
The order of modification may attribute to the sharp decrease in overall viability as 
observed with increasing sample amount. From the viability data (Figure 3-10), we can 
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see particles hybridized with QD first (Path A) exhibit a higher relative cellular viability 
than those functionalized with anti-IgG first (Path B). The addition of anti-IgG to the 
hybridized GNP-QD resulted in the capping of the amine groups found on the surface of 
the QD leading to a minimized exposure to the cell. On the other hand, the addition of 
QD to the bioconjugated GNP-anti-IgG may have resulted in the presence of QD 
hybridizing to carboxylic acid groups on the surface of the anti-IgG antibody, thereby 
exposing its amine-rich surface. The resultant exposure of the amine rich QD to the cell 
may have contributed to the decreased viability seen with the GNP-anti-IgG/QD. As 
demonstrated by Kim et al.34 with polysterene-modified nanoparticles, different terminal 
functional groups can interfere with the natural progression of the cell cycle. The 
presence of amine groups caused the cell cycle to arrest at G1/S and G2/M phases in 
mitosis whereas carboxyl groups did not. In our model, the order of modification was 
vital to limiting the exposure of primary amine groups with the UTA-6 cells. 
Nanoparticles modified with QD first exhibited greater cell viability overall. 
Furthermore, the significant difference in relative viability (p < 0.001) between the GNP-
QD/anti-IgG and GNP-anti-IgG/QD can be observed as shown in Figure 3-11. GNP-anti-
IgG/QD exhibited a markedly lower viability at higher amounts (20 μg +) of introduced 
particles. Therefore prompting an attempt to mitigate the lowered viability in general 
through the incorporation of PEG, which has been shown to enhance biocompatibility.24–
26,29  Figure 3-11 shows the relative cell viability of the hybrid GNP with different 
surface modification results of the investigation on the addition of PEG.A series of 
analyses have demonstrated both order and PEG can play a role in affecting cellular 
viability. The PEG was able to increase relative viability of GNP-anti-IgG/QD 
significantly (p = 0.0019), but not to the levels shown by Path A. Shown in Figure 3-11, 
the PEG substantially increased the overall viability, even with increasing sample 
amount. However, the addition of PEG to Path A, though having a negative impact, 
maintained viability above 65% at 40 mg while Path B dropped below 60%. 
The addition of PEG to Path A modification may have promoted an increased 
accumulation at the site of interest in combination of a recognition element, in our case 
the anti-IgG.35 The addition of PEG increases a free energy change during endocytosis 
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process allowing for a more readily internalized particle.36 The direct result of enhanced 
internalization into the cytoplasm may lead to disruptions in cytoskeletal formations. 
Through immunostaining Gupta et al.37 demonstrated their nanoscopic GNP (37  0.84 
nm) caused the formation of vacuoles within the cell body resulting in the anisotropic 
formation of F-actin with poorly developed filament bundles. The relative cell viability of 
our model corroborates with what Gupta et al. observed, a decrease in overall viability 
due to internalization. Furthermore, these cellular filaments were observed to protrude 
from the cell as a result of internalization. 
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CHAPTER 4  
To quantitatively assess our upconversion nanoparticles (UCNPs) functionalized with 
anti-human vascular endothelial growth factors (VEGF) as a treatment for angiogenic 
prone diseases by binding to extracellular VEGF. The UCNPs provides bimodal imaging 
(ie: MRI and fluorescent) and tracking capabilities. Our endeavour is to assess the anti-
angiogenic properties of the UCNP model in comparison to bare-antiVEGF as a means 
for alternative treatment for angiogenic prone diseases such as cancer and wet-age 
related macular degeneration with diagnostic relevance. 
The contents of this chapter are a compilation of two original research articles; a) WH. 
Tse, S. Yang, and J. Zhang. Bimodal imaging compatible theranostic nanoparticles for 
anti-angiogenic treatment. b) WH. Tse, L. Chen, CM. McCurdy, CM. Tarapacki, BA. 
Chronik, and J. Zhang. Biocompatible imaging with NaGdF4: Er3+, Yb3+ Upconversion 
Nanoparticles on HUVEC Cells. (To be submitted August 2017). 
4 BIMODAL IMAGING COMPATIBLE THERANOSTIC 
NANOPARTICLES FOR ANTI-ANGIOGENIC 
TREATMENT 
4.1 Introduction 
Nanoparticle theranostic applications for drug delivery are a state-of-the-art concept to 
provide both biomedically relevant mode of imaging tracking and therapeutics in one 
model. Current technology is limited by bioavailability of therapeutics and imaging 
limitations or lack thereof which prevents it from achieving its full potential. 
Nanoparticles provide an optimal foundation for the development of next generation 
multifunctional and multi-disease viable therapeutic options. One application of 
nanoparticles is for the treatment of angiogenic prone diseases such as cancer and wet 
age-related macular degeneration (AMD) with anti-vascular endothelial growth factors 
(anti-VEGF) for adjunct and primary care, respectively.1–4  
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In cancer it is well documented angiogenesis is required for solid tumor growth.5,6 
Clinical applications of anticancer agents aside from chemotherapy rely on anti-VEGF as 
adjunct treatments to greatly improve efficacy of treatment.7 Bevacizumab, was the first 
VEGF inhibitor approved for use to treat metastatic colorectal cancer, which improved 
survival of patients from 15.6 to 20.3 months.5,7 Other proposed applications include the 
use of Mogamulizumab, an anti-chemokine receptor, for the treatment of T-cell 
leukemia-lymphoma8 and Apatinib for metastatic breast cancer.1 For treatment of 
pathogenic angiogenesis, antibody therapy act to inhibit various pathways in the 
angiogenic process stimulated by the binding of VEGF to its respective receptors which 
can promote endothelial cell survival, new blood vessel formation and remodeling, and 
increased vascular permeability.6,9,10  
Wet AMD is characterized by choroidal neovascularization, choroidal angiogenesis as a 
result in the imbalance between proangiogenic VEGF and anti-angiogenic pigment 
epithelium-derived factor.11 The pathogenesis of this disease is also multifactorial with 
age and vascular trauma being severe risk factors.12 Vision loss and in extreme cases 
irreversible damage to the retina results as vascular leakage causes an increase in ocular 
pressure leading to retinal separation.4,13–15 Antibody treatments such as bevacizumab, 
ranibizumab, and various others have been routinely used to treat wet AMD with 
success.13,14,16,17  
Nanoparticles have been proposed to address specific shortcomings of current 
technologies. Nanoparticles have the potential to increase efficacy and improve drug 
delivery which decreasing adverse effects by modulating both pharmacokinetic and 
pharmacodynamic profiles of drugs for enhancing the therapeutic index.18 Drugs or 
antibodies may also be loaded into nanosized carriers for increased in vivo stability, 
extend the blood circulation time, and allow for controlled release.3,19–21 Nanoparticles 
may also provide a solution for physical barriers to efficacious treatment such as the 
blood-retina barrier and corneal barrier.19 Nanoparticle applications for cancer have been 
proposed to exploit the enhanced permeability and retention effect (EPR), where 
nanoparticles will passively accumulate in a tumor due to the presence of leaky 
intratumoral blood vessels where fenestrations are between 100 – 780 nm in size.18,22 
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Nanoparticles can be repurposed for alternative treatments of wet-AMD are desired as 
current therapy requires frequent injections to maintain relevant bioavailability and have 
off-target effects.23 Suitable nanocarriers for ocular treatments have been developed using 
biodegradable chitosan and gelatin for sustained drug release.3,19 
In addition, to improving drug accumulation, therapeutic efficacy, sustained drug release, 
and increasing drug solubility,  nanoparticles offer a unique set of physical characteristics 
suitable for ferrying therapeutic drugs and providing a platform for biomedical 
imaging.24–26 As a direct result of material-based properties, the size, shape, structure, and 
surface properties can be tailored to suit the needs of any application.25,27 For instance, 
biocompatible polymeric nanoparticles (ie: chitosan, gelatin, PLGA, etc.) have 
demonstrated great biocompatibility and drug encapsulation efficiency suitable for in vivo 
sustained drug release.27–29 
Biocompatible imaging nanoparticles have been developed to bridge the gap between 
nanocarriers with theranostic imaging. Current renditions of imaging compatible entities 
are fluorescent dyes, which are susceptible to photobleaching and potentially genotoxic if 
the excitation source is near the UV range.30–32 New advancements in lanthanide based 
nanoparticles have provided the ideal bimodal imaging entity compatible with both 
magnetic resonance imaging (MRI) and upconversion fluorescence imaging. Fluoride-
based lanthanide cores provide a stable matrix for the doping of lanthanide ions 
responsible.33 Gadolinium (Gd), Ytterbium (Yb), and Erbium (Er) have demonstrated 
satisfactory imaging properties for bimodal imaging.34–37 Gd, a paramagnetic metal 
employed in clinical MRI, has been demonstrated by Zhou et al. to provide a stronger T1-
weighted imaging signal in the nanoparticle form.38 The most interesting component of 
the lanthanide doping is the phenomenon of multiphoton upconversion fluorescence 
which convert near-infrared light (NIR) into higher energy emissions into the visible 
colour spectrum.39–41 This phenomenon exploits the optical transmission window for 
deeper light penetration, damage to cells, reduced light scattering, and increased image 
contrast.36,38 This characteristic would be compatible in ophthalmology where optical 
coherence tomography is used to assess the morphology of the eye.40 
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Figure 4-1. Schematic of the upconversion nanoparticle antibody model. The UCNP is 
functionalized with the anti-VEGF antibody to produce a theranostically relevant 
nanoparticle with bimodal imaging capabilities and anti-angiogenic treatment. 
 
 
 
 
 
 
 
 
We propose a fluoride-based upconversion nanoparticle (UCNP) core with anti-human 
VEGF (anti-VEGF) bioconjugated on the surface for the purpose of anti-angiogenesis 
treatment with bimodal imaging affinities (Figure 4-1). The nanoparticle model will be 
assessed for its potential to be tracked via upconversion fluorescence and traced by 
magnetic resonance. Furthermore, intend to contrast and compare the nanoparticle model 
with respect to its non-conjugated anti-VEGF counterpart to quantify potential 
differences in its anti-angiogenic properties. 
4.2 Materials and Methods 
4.2.1 Study Design 
The UCNPs functionalized with anti-VEGF was assessed on human umbilical vascular 
endothelial cells (HUVEC) for biocompatibility and anti-angiogenic effects. HUVECs 
were grown on a 2% gelatin (w/w) matrix to promote adhesion and provide a suitable 
foundation for immunocytochemistry (ICC). Furthermore, the UCNP model was assessed 
for bimodal imaging compatibility for magnetic resonance and fluorescent imaging. 
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Figure 4-2. Synthesis schematic of upconversion nanoparticles modified with PEI. The 
synthesis occurs in a one pot reaction to grow the NaGdF4: Er, Yb UCNPs. 
HUVECs were grown in Medium 131 supplemented with microvascular growth 
supplement (MVGS), 100 units/mL penicillin and 100 μg/mL streptomycin, and 5 µg/mL 
amphotericin B at 37°C with 5% CO2 under sterile conditions. 
 
4.2.2 UCNP synthesis surface modification with PEI 
Water soluble Gd-based UCNPs doped with polyethylenimine (PEI), Er, and Yb were 
synthesized according to the method used by Longyi et al. (Figure 4-2).33 In short, 1.6 
mmol gadolinium(III) nitrate hexahydrate (Gd(NO3)3·6H2O), 0.36 mmol ytterbium(III) 
nitrate pentahydrate (Yb(NO3)3·5H2O), 0.38 mmol erbium(III) nitrate pentahydrate 
(Er(NO3)3·5H2O), 8 mmol sodium fluoride (NaF), 0.7 g PEI (MW ~ 800 by LS, average 
Mn ~ 600 by GPC), and  30 mL of ethylene glycol; all purchased from Sigma-Aldrich, 
were combined in a one pot synthesis reaction to produce NaGdF4: Er, Yb (Gd-UCNPs). 
The solution was heated to 198°C and held for 6 hours with nitrogen under reflux to 
promote UCNP nucleation and growth. UCNPs were then collected by centrifugation and 
purified with ethanol thrice. UCNPs were dried with a lyophilizer. 
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4.2.3 UCNP functionalization with anti-VEGF 
Polyclonal anti-human VEGF produced in goat (V6627, Sigma-Aldrich) was combined 
with the as-synthesized UCNPs in a pH 8.5 borate buffer under constant agitation for 2 
hours to facilitate a dehydration reaction to covalently link the anti-VEGF to the UCNPs 
surface. From here on, the bare UCNP shall be referred to as Gd UCNP and the anti-
VEGF modified UCNPs shall be referred to as Gd-antiVEGF UCNP. 
For applications in ICC, Gd-antiVEGF UCNPS were tagged with FITC using the borate 
buffer to provide fluorescent tracking during confocal imaging as it is not equipped for 
upconversion fluorescence imaging. 
4.2.4 Materials Characterization 
UCNPs were characterized with transmission electron microscopy (TEM; Phillips CM-10 
at 80 kv) to determine size (n = 200) and ICP-MS (Agilent 7700) to determine lanthanide 
composition. The diameter of the UCNPs from the TEM images was analyzed with 
ImageJ software (National Institutes of Health, USA). Hi-resolution TEM (HRTEM, 
FEM Titan 80-300 HB, Gatan 866 model) was used to verify the crystalline structure. 
The surface modification with PEI was confirmed with Fourier Transform Infrared 
(FTIR, Bruker Vector 22), in the range of 600–4500 cm-1 with a resolution of 4 cm-1 and 
64 scans. 
4.2.5 Quantification of anti-VEGF conjugation 
Anti-VEGF conjugation was quantified with a protein assay measuring the absorbance of 
the BCA Assay results at 490 nm. Using a 5 point standard curve as shown in Figure 4-3, 
the amount of anti-VEGF conjugated directly to the surface of the UCNPs was 
determined.  
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Figure 4-3. Anti-VEGF protein assay standard curve. 5 point standard curve for 
quantifying the directly bioconjugated anti-VEGF. 
 
 
 
 
 
4.2.6 UCNP fluorescence 
Upconversion fluorescence was assessed with a Spectrofluorometer (QuantaMaster™ 40, 
Photon Technology International Inc.) equipped with an infrared laser. We assessed the 
fluorescence of the UCNPs with various laser powers from 0.5 Watt to 1.5 Watt. 
4.2.7 Magnetic Properties 
Magnetic resonance imaging compatibility was assessed with a vibrating sample 
magnetometer (VSM, Lake Shore 7407) to determine magnetic susceptibility and with a 
GE-MR 750 MRI at 3T as per the methods of Rohrer et al.42 and Haedicke et al43. 
Various amounts of UCNPs were prepared in a 1.5% agarose gel with TBE buffer to 
yield a Gd ion concentration of 0.133 to 5.337 mM. Vasovist, a commercially available 
Gd contrast agent, was used as comparison.44 
4.2.8 Cell viability 
Biocompatibility was assessed colorimetrically with a MTT cell viability Assay (Sigma- 
Aldrich) in triplicate incubated with 10, 50, 100, 250, and 300 μg/mL of the Gd-UCNP, 
Gd-antiVEGF UCNPs, and the anti-VEGF equivalent for 24 hours with 8, 000 cells. The 
anti-VEGF equivalent is the amount of anti-VEGF that should be bioconjugated onto the 
Gd-antiVEGF UCNPs. 
4.2.9 Immunocytochemistry 
8 chambered culture slides (Eppendorf) were groomed for ICC by coating them with a 
2% solution (w/w) of gelatin (Figure 4-4). The 2% solution was made by dissolving the 
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Figure 4-4. Chamber preparation for immunocytochemistry. A) 2% gelatin solution was 
loaded into the 8 well chambers for 2 hours at 37°C prior to aspiration and drying to form 
a growth matrix for the HUVECs. B) Cells were seeded into the sterile chambers in 
simulate angiogenic conditions with the addition of PMA. 
gelatin into deionized water at 37°C then sterilized in an autoclave. Enough of the gelatin 
solution to cover the entirety of the well was added and left for 2 hours at 37°C to settle. 
The solution was then aspirated gently and the gelatin coated plates were left to dry 
overnight. 
Approximately 100,000 cells were seeded into each well. To mimic angiogenesis, cells 
were treated with 50 µg/mL of phorbol 12-myristate 13-acetate (PMA) for 24 hours prior 
to treatment with 10 and 100 µg/mL of Gd UCNP, Gd-antiVEGF UCNP, and anti-VEGF 
equivalent for another 24 hours before ICC in triplicate. It is known PMA is capable of 
accelerating endothelial cell migration, vascular network formation, and its 
stabilization.45,46 
HUVECs were fixed to the gelatin matrix with 4% formalin for 2 hours. Cells were 
permeabilized with a 0.1% Triton X-100 solution prepared with PBS for 5 minutes. 
TRITC-phalloidin prepared according to the manufacturer’s instructions was incubated 
with the cells at room temperature for 40 min to stain the actin. DAPI, prepared as per the 
manufacturer’s instructions was added to the cells for 15 minutes. In between each step, 
cells were thrice washed gently with PBS (pH 7.4). Cells were then treated with anti-fade 
and sealed with a cover slip for confocal imaging (Zeiss LSM510 Duo). 
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Figure 4-5. Upconversion antibody model characterization by TEM. A) Bare Gd-UCNP 
visualized by TEM. As shown in the inset, the anti-VEGF (outlined in red) was 
visualized on the Gd-antiVEGF UCNP. B) HRTEM shows the highly crystalline 
structure of the UCNP. The interplanar distance between adjacent lattice planes was 
0.312 nm. 
Cell morphology was visualized and cell length was measured to verify angiogenesis and 
determine the anti-angiogenic effects of anti-VEGF. Furthermore, we determined the 
localization of the FITC tagged Gd-antiVEGF UCNP with respect to the cell structure to 
verify internalization and extracellular localization. Images were captured from at least 4 
separate sections of each chamber such as n = 120 cells from each treatment were 
documented. Image processing was performed with Image Pro Premier (Media 
Cybernetics Inc., Rockville, MD). 
4.2.10 Statistical Analysis 
Statistical significance was determined using GraphPad Prism (GraphPad Software Inc, 
La Jolla, CA, USA). T test was used to assess UCNP size as a result of functionalization. 
Cell viability was assessed with a t test and two-way ANOVA to determine the effect of 
concentration. Changes in cell length and treatment concentration were assessed with a 
one-way ANOVA. Statistical analyses was performed at the 95% confidence level. 
4.3 Results 
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Figure 4-6. FTIR spectrum of the PEI modified NaGdF4: Er, Yb UCNPs. –NH- 
stretching was confirmed by the broad 3300 cm-1 peak. –OC-NH- bending was 
demonstrated by the small 1640 cm-1 peak. Amine groups were shown by the 1510 cm-1 
peak. The stretching vibrations of –CH2- and C-C bonds are visualized at 2300 and 1400 
cm-1 respectively. 
As shown in Figure 4-5A, the TEM images was able to visualize the bioconjugated anti-
VEGF onto the Gd-UCNPs. HRTEM, Figure 4-5B, determined the interplanar distance 
between adjacent lattice planes to be 0.312 nm, which corresponds to a (1 1 1) plane of 
the NaGdF4 (JCPDS 27-0697). PEI surface modification of the Gd-UCNPs was 
confirmed by FTIR, shown in Figure 4-6, demonstrates a broad peak at 3300 cm-1 caused 
by –NH- stretching and a peak at 1510 cm-1  resultant of the vibration of amine groups. 
UCNP size as a result of anti-VEGF functionalization and amount bioconjugated can be 
seen on Table 4-1. Anti-VEGF significantly increased the size of the UCNP from ~ 53 
nm to ~ 106 nm (p < 0.0001). Protein assay determined 9.48 µg of anti-VEGF was 
bioconjugated onto the surface of the 1 mg Gd-UCNP. Physical quantification by ICP-
MS of the constituents Gd, Er, and Yb is reported in Table 4-2. 
 
 
 
 
 
 
 
 
 
 
 
Table 4-1. Physical characterization of Gd-UCNPs. 
Parameter Gd-UCNP Gd-antiVEGF UCNP 
Diameter (nm) 52.95 ± 12.98* 105.50 ± 35.28* 
Anti-VEGF 
(µg/ mg Gd-UCNP) 
N/A 9.48 ± 1.92 
*Significant increase on size was resultant of anti-VEGF bioconjugation (p<0.0001). Size 
was determined by measuring individual particles in TEM images (n = 200). 
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Table 4-2. Percent composition of Gd, Er, and Yb in UCNPs 
Sample Composition (%) 
Gd 41.97 
Er 10.80 
Yb 11.12 
Upconversion fluorescence of the Gd-UCNPs was assessed at a concentration of 0.7 
mg/mL, as shown in Figure 4-7, stimulate by a 980 nm near-infrared laser of various 
power settings; 0.5 Watt to 1.5 Watt. The upconversion signal could be detected at 660 
nm and 540 nm. 
 
 
 
 
 
 
 
 
 
Magnetization of the UCNPs was assessed by VSM. Figure 4-8 depicts the 
magnetization of the UCNPs at various biological relevant temperatures to be 
paramagnetic. Furthermore, at an applied field of 1 T, the magnetization was determined 
to be 1.3 emu/g. 
 
 
Figure 4-7. Upconversion fluorescence spectra of the NaGdF4: Er, Yb UCNPs. Laser 
excitation of 980 nm at various powers 0.5 to 1.5 Watt. 
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Figure 4-8. Magnetization of the UCNPs. At various biologically relevant temperatures, 
the magnetization was found to be approximately 1.3 emu/g and paramagnetic. 
 
 
 
 
 
 
Analysis of the UCNPs in a 3 T MRI using a fast spin echo-inversion recovery sequence 
with various inversion times for T1-weighted imaging is shown in Figure 4-9. Imaging 
parameters were as follows: inversion time (TI) = 200, 500, and 2000 ms; flip angle of 
160°. Highlighted in red is the 1% Vasovist and water as references. 
 
 
 
 
 
1 2 3 4 5 6 7 8 
A 0 0.133 0.267 0.400 0.534 0.667 0.801 0.934 
B 1.067 1.201 1.334 1.468 1.601 1.734 1.868 2.001 
C 2.135 2.268 2.402 2.535 2.668 2.802 2.935 3.069 
D 3.202 3.335 3.469 3.602 3.736 3.869 4.003 4.136 
E 4.269 4.403 4.536 4.670 4.803 4.936 5.070 5.203 
F 5.337 
     
1% 
Vasovist 
Water 
Figure 4-9. UCNP T1-weighted signal with 3 T magnetic field. Signal as a result of 
various inversion times (TI). Outlined in red are the references; 1% Vasovist and water 
respectively. Sample concentrations are listed in mM of Gd suspended in 1.5% agarose 
gel. 
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Figure 4-10. Relative cell viability of HUVECs with various treatments for 24 hours. A) 
Cell viability of treated with Gd-UCNP, Gd-antiVEGF UCNP, and anti-VEGF 
equivalent. UCNP exhibited a significantly higher viability compared to anti-VEGF 
based treatments (p < 0.05). B) Gd-UCNP exhibited a significantly higher viability than 
Gd-antiVEGF UCNPs (p = 0.0114). 
 
Relative ell viability of the HUVECs treated with Gd-UCNP, Gd-antiVEGF UCNP, and 
the anti-VEGF equivalent demonstrated significant difference in viability between Gd-
UCNP and the anti-VEGF based treatments (Figure 4-10A; p < 0.05). Relative viability 
of anti-VEGF based treatments decreased from 85% viability to below 70% viability 
when increasing concentration from 10 µg/mL to 100 µg/mL. Gd-UCNP demonstrated an 
increase in viability instead. Comparing the relative viability of Gd-UCNP to Gd-
antiVEGF UCNP at concentrations of 50, 100, 250, and 300 µg/mL, there was a 
significant decrease cell viability between the two samples (Figure 4-10B; p = 0.0114). 
Gd-antiVEGF caused a significant decrease in viability to approximately 70% with 
increasing concentration whereas, Gd-UCNP remained above 80%. 
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Figure 4-11. Change in cell length as a descriptor for angiogenesis. The cell length 
assessed indicated the anti-VEGF and Gd-antiVEGF UCNPs was significantly shorter 
than those treated with Gd UCNPs (p < 0.0001) after incubation for 24 hours. PMA and 
Gd UCNPs were not significantly different in cell length but were significantly longer 
than the control cells. 
 
 
Figure 4-11 depicts the effect of anti-VEGF, Gd UCNP, and Gd-antiVEGF UCNP on 
HUVECs treated with PMA. Analysis indicated significant differences (p < 0.0001) 
between the treatments. At the low concentration of 10 µg/mL, the Gd-AntiVEGF 
UCNPs and anti-VEGF equivalent did not cause significant changes in cell lengths 
relative to the control, which was not treated with PMA. Cells treated with PMA and Gd-
UCNPs exhibited significantly elongation though not significantly different to each other. 
In general, the anti-VEGF equivalent treatments and Gd-antiVEGF UCNPs exhibited 
shortened cell length in comparison to cells treated with just the Gd UCNPs. 
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Figure 4-12. Confocal images of HUVECs treated with FITC tagged Gd-antiVEGF 
UCNPs. A) Confocal images depicting the stained actin (red), cell nucleus (blue) and 
FITC tagged Gd-antiVEGF UCNPs (green). B) Corresponding isoform image. C) 
Magnified isoform showing the cellular interaction of Gd-antiVEGF UCNP. D) Z-stack 
of an endothelial cells demonstrating the intracellular location of the Gd-antiVEGF 
UCNP relative to the nucleus. 
HUVECs incubated with Gd-antiVEGF UCNPS tagged with FITC were processed into 
isoforms to provide a clear image of the fluorescence signal and displayed in Figure 4-
12. The confocal fluorescent image of the HUVECs stained for the actin (red), cell 
nucleus (blue), and the Gd-antiVEGF UCNPs (green) is shown in Figure 4-12A. The 
corresponding isoform image in Figure 4-12B, presents a clearer and sharper image of 
the staining. As shown in Figure 4-12C, the magnified HUVEC is interacting with the 
Gd-antiVEGF UCNPs on the external surface. The z-stack image of the corresponding 
cell is shown in Figure 4-12D. The effect of the Gd-antiVEGF UCNPs (C) can observed 
in Figure 4-13 relative to the control (A) and the PMA treated cells (B). The cells treated 
with Gd-anti-VEGF exhibited less coordination and elongation in comparison. 
 
 
 
 
 
z 
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Figure 4-13. Confocal images of HUVEC cells. A) Control cells demonstrated some 
coordination. B) PMA treated HUVECs exhibited elongation and coordination into am 
immature vascular network C) Gd-antiVEGF UCNPs treated cells inhibited the 
elongation and formation of an immature vascular network. 
 
 
 
 
 
4.4 Discussion 
Our UCNPs functionalized with anti-VEGF provides insight into a shift from traditional 
treatment and imaging strategies to nanoparticle oriented technology. Our theranostic 
model was developed to be compatible for tracking by magnetic resonance imaging and 
fluorescent imaging with the purpose of counter acting pathological angiogenesis. 
The bimodal tracking capabilities by MRI and fluorescence was studied by VSM, MRI, 
and spectrophotometrically with a NIR laser (λex = 980 nm). With respect to 
upconversion fluorescent imaging as shown in Figure 4-7, the detected fluorescence was 
presented as a function of varying laser powers suitable for biomedical applications. The 
observed emission spectra was strongly affect by laser power as confirmed by Wang et 
al.37 The fluorescence of the 0.7 mg/mL of UCNPs stimulated at low power (0.5 W) was 
observed to relatively weak. Furthermore, the upconversion nanoparticles has been 
demonstrated by various groups to demonstrate strong fluorescent emissions as a result of 
the multi-photon upconversion process.47,48 Compatibility with MRI as displayed in 
Figure 4-9, demonstrates a potential to be employed as a tracking agent and contrast 
agent. Signal from Gd concentrations as low as 0.1 mM or lower have been detected.38,49 
In depth investigation of the lanthanide dopants concentration may provide an optimal 
ratio of the dopants to maximize either upconversion fluorescence or MR signal. 
However, it is possible to also increase or decrease the specific dopants to improve the 
detected signal of choice; Gd for MRI or Er/Yb for upconversion fluorescence. 
Analysis of cell viability (Figure 4-10A) of the anti-VEGF equivalent, Gd UCNPs, and 
Gd-antiVEGF UCNPs demonstrated a viability of above 85% at a low concentration (10 
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µg/mL) and decreased at  a higher concentration of anti-VEGF was introduced to the 
HUVECs causing a significant decrease in viability, which is reflective of the anti-
angiogenic properties of the anti-VEGF. Assessment of the Gd UCNPs vs Gd-antiVEGF 
UCNPs viability over an increased range of concentrations (Figure 4-10B) also 
demonstrated the anti-VEGF’s anti-angiogenic properties at elevated concentrations. As 
the MTT assay is a measure of viability, the anti-VEGF’s ability to neutralize the VEGF 
signal is reflected by the decreased viability as they lose their proliferative 
stimulation.50,51   
As Figure 4-11 suggests, the lengthening and shortening of the cells is reflective of the 
angiogenic process as the cells proliferate and migrate to form novel vascular structures. 
The addition of PMA as shown by Osaki et al.45 and Goodwin46 is able to stimulate the 
formation of such structures. The addition of the anti-VEGF equivalent and Gd-
antiVEGF UCNPs was able to significantly shorten the cells which signifies the 
inhibition of elongation; a characteristic of anti-angiogenesis. The effect can be observed 
in Figure 4-13. These results are reflective of the anti-VEGF treatments currently 
employed for treating AMD and cancer.8,13,16 
Our theranostic model is promising as it is compatible with bimodal imaging for tracking 
and imaging for in vivo applications. As demonstrated by various groups, the bare 
UCNPs are capable of bimodal imaging with success  in vitro and in vivo rodent models 
capable of accumulating with in tumours.49,52–54 Our model was able to exhibit similar 
properties for bimodal imaging and provided anti-angiogenic effects in addition to that. 
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CHAPTER 5  
To quantitatively assess our biosensor for detecting glucose with high sensitivity and low 
concentration in tears from rats. The QD-based biosensor aims to non-invasively assess 
tear glucose as a reflection of blood glucose using Forster Resonance Energy Transfer 
which is also known as Fluorescence Resonance Energy Transfer. The interaction 
between protein and QDs is vital to the optimal performance of the biosensor. 
The contents of this chapter was previously published in the Biosensors and 
Bioelectronics: L. Chen*, W.H. Tse*, Y. Chen, M.W. McDonald, J. Melling and J. Zhang. 
Nanostructured biosensor for detecting glucose in tear by applying fluorescence 
resonance energy transfer quenching mechanism. Bionsensors and Bioelectronics. 2017: 
91;393-399. doi: dx.doi.org/10.1016/j.bios.2016.12.044. 
*authors contributed equally 
5 NANOSTRUCTURED BIOSENSOR FOR DETECTING 
GLUCOSE IN TEAR BY APPLYING FLUORESCENCE 
RESONANCE ENERGY TRANSFER QUENCHING 
MECHANISM. 
5.1 Introduction 
Tear fluid cleans and lubricates the eye while nourishing. Over 20 components have been 
found in tears, including salt water, proteins, glucose, and some small metallic ions, etc.1 
Diagnosis of biomolecules in tear fluid pertaining to ocular diseases such as ocular 
rosacea, have been performed primarily by clinicians to examine the high molecular-mass 
glycoproteins in tears.2 The detection of ocular glucose dates back to 1930.3 Following 
that, Michail and his collaborators first demonstrated the level of glucose in tears is often 
elevated in diabetic patients.4 Sen and Sarin studied over 200 cases, their statistic results 
indicated the blood glucose is about 2 times higher in diabetic patients than that in non-
diabetics, whereas tear glucose levels are ~5 times higher in diabetics than that in the 
general population.5 In past decades, different research groups found a definite 
relationship between tear glucose and blood glucose, concluding hyperglycemia could be 
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detected by measuring tear glucose levels.6–8 Recent studies indicate tear glucose mean 
values were 0.35 ± 0.04 mmol/L and 0.16 ± 0.03 mmol/L, for patients with diabetes and 
healthy subjects, respectively.9 It is also noted time lag in measuring tear glucose is 
common to other glucose meters as it takes 5–15 min to allow the change of glucose in 
blood to eventually reflect in tear/interstitial fluids;10 while it can be solved by a series of 
calibrations.11,12  
However, it is very difficult to acquire enough tear samples in a short period. 
Furthermore, the concentration of glucose in tears is much lower than that in blood. Very 
few methods so far can measure such low concentration of glucose in a rapid fashion.13,14 
Compared to many other techniques, Forster or fluorescence resonance energy transfer 
(FRET), an inexpensive and very sensitive method, has been used in molecule imaging 
and glucose test.15–17 It is a distance-dependent energy transfer from a fluorophore donor 
(D) to a fluorophore acceptor (A) in a nonradioactive process. When the distance of the 
two fluorophores is very close (< 10 nm), the excited D will transfer some of its energy to 
excite A that then emits light at a longer wavelength.17 Using FRET technique for 
detecting the competitive reactions of glucose and other polysaccharide, such as dextran, 
to concanavalin A (Con A), a protein, may result in accurate and convenient measures.18–
20 However, fluorophores/organic dyes used in FRET pair are subject to low fluorescent 
intensity, and poor signal responses influenced by the decay of chromophores and 
external environment.21 Fluorescence nanostructures have been recognized as excellent 
materials used in FRET sensor due to their photo-stability and narrow emission peaks.22 
We developed a nanostructured sensor by using fluorescence resonance energy transfer 
(FRET) technique which is able to be incorporated into hydrogel-based contact lenses for 
measuring low concentration of glucose directly.23,24 While, most reported FRET sensors 
have an inversely proportional relationship between the ratio of the fluorescence intensity 
of the donor to that of the acceptor (ID/IA) and the amount of the targeted molecules 
because the rate constant of the energy transfer, kFRET, decreases while the distance 
between the FRET pair increases. Consequently, most reported FRET sensors have 
significant measurement errors when detecting the increase of concentration of the 
targeted molecules because of the low fluorescence signals-to-noise ratio. 
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Quite recently, fluorescent quenching-based assay in which the donor fluorescence can be 
quenched by the acceptor without analytes has shown significant advantages in 
biosensing, as it allows the restored fluorescence signal proportional response to the 
concentration of target analytes and lower background fluorescence.15,25 Consequently, a 
new nanostructured sensor by applying FRET quenching mechanism is developed here to 
detect small concentration of tear glucose from very small volume of tear samples in a 
fast and accurate fashion. 
Figure 5-1A displays a FRET pair-labeled Concanavalin A (Con A), an enzyme with 
specific affinity to glucose.18–20 The donor in this designed FRET transducer is made of 
quantum dots with an emission (λem) in the visible range; the acceptor is dextran-bound 
malachite green (MG) which has an absorption at the same wavelength of the emission of 
the quantum dots. The emitted fluorescence of the quantum dots can be quenched by 
malachite green through the FRET mechanism. In the presence of glucose, the binding 
between Con A and dextran is out competed by the affinity of Con A for glucose. As a 
result, dextran bound MG will not quench the fluorescence of quantum dots, and 
therefore fluorescence intensity is restored. The change in fluorescence intensity is 
correlated to the amount of glucose reacting with Con A.  
In addition, we would like to further develop a dual-method for detecting glucose through 
both of fluorescence spectra and fluorescence images. To quickly and accurately detect 
the amount of glucose in a very small volume of tear sample by measuring the changes of 
fluorescence intensity of the sensor, the numerous nanostructured FRET sensors are 
immobilized on a single ZnO nanorod (NR) which have a high surface area to volume 
ratio as shown in Figure 5-1B. This design allows numerous FRET biosensors located at 
a nanoscale, and therefore, is able to amplify the resolution of the sensor.26 Moreover, to 
quickly and accurately detect the amount of glucose in a very small volume of tear 
sample by fluorescence images, the designed pattern made of ZnO NR array is utilized 
here which can be recognized easily through fluorescence image process. The pixel 
intensity values in a taken fluorescence image corresponding to the concentration of 
glucose can be calculated through an imaging process. Consequently, the patterned 
nanostructured FRET sensor on silicone hydrogel can realize the dual modulation for 
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monitoring glucose level in tear samples through both of fluorescence spectrum and 
calibrated image pixel value. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.2 Materials and Methods 
5.2.1 Study Design 
The glucose sensor was designed and optimized for low sensitivity detection of glucose 
change on ZnO nanorods grown on a silicone substrate. The sensor was designed for a 
quenching mechanism to detect glucose as low as 0.03 mM and up to 3 mM where an 
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Figure 5-1. Illustration of the designed FRET transducer made of ConA-conjugating 
quantum dots (donor) and MG (acceptor) for detecting glucose. Competitive affinity for 
glucose displaces MG to restore the quenched fluorescence. (b) Immobilization of the 
nanostructured FRET transducers on ZnO nanorod array deposited on silicone hydrogel. 
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increase in glucose concentration linearly correlated with an increase in detectable 
fluorescent intensity. 
Glucose sensor effectiveness was assessed on Sprague-Dawley rats (Charles River 
Laboratories, St. Constant, Quebec, Canada) with induced diabetes. Tear glucose 
collected with capillary tubes and quantified with our fluorescent glucose sensor was 
compared and contrasted to blood glucose measured with a glucose meter (Freestyle Lite 
Blood Glucose Monitoring System, Abbott Diabetes Care Inc., Mississauga, Ontario).  
Our substrate-based glucose sensor's fluorescence was assessed and captured with a 
handheld USB powered portable digital microscope, MiScope, from Zarbeco. Images 
were processed in Matlab to determine the relationship between fluorescence intensity 
and glucose concentration in the samples. 
5.2.2 Fabrication of patterned QDs decorated with ZnO nanorod 
arrays on silicone 
Hydrogel Cadmium selenium/zinc sulfide (CdSe/ZnS) core-shell quantum dots (QDs) 
were chosen as the donor of the FRET pair. The core-shell QDs were further 
functionalized with amine groups.27 Briefly, CdSe/ZnS (20 mg) dissolved in 3 mL of 
chloroform was mixed with a solution of cysteamine (Cys) hydrochloride (100 mg) 
dissolved in 5 mL of water. The solution was sonicated until the chloroform layer became 
clear. The remaining cysteamine was reacted with the addition in excess of 2-
mercaptoethanol (20 mmol/L). CdSe/ZnS/Cys QDs were purified by threefold 
centrifugation (15 min at 10000 rpm) and rinsed with ethanol. Purified particles were re-
dispersed in water. 
Silicone hydrogel with 150 μm in thickness was produced using a photochemical 
process.28 The patterned ZnO nanorod (NR) array was fabricated on the silicone hydrogel 
by a photolithographic lift-off process as visualized in Figure 5-2. Photoresist (PR; 
Shipley 1827) was deposited on the ZnO NR arrays by spin coating and exposed to UV 
(Karl Suss MJB3, Hg Arc Lamp) irradiation over a patterned photomask for 30 seconds 
followed with post-baking. After the post-baking, the non-irradiated area was treated with 
a developer (Shipley Microposite MF-319) for 2 min and rinsed with DI water. A wet 
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chemical etching method was used to remove the ZnO area without PR by immersion in a 
diluted acetic acid solution. After washing with DI water, the remaining PR was washed 
away using ethanol. The final products were dried for further application. 
The surface modification of the patterned ZnO NR array with amino groups is described 
as follows; the ZnO NR array on silicone hydrogel was immersed into 2 mL DMSO and 
270 μL 3-aminopropyltriethoxysilane (APS) suspension. After having reacted at 120 °C 
for 2 h, the ZnO hydrogel was taken out and washed with ethanol to remove unreacted 
compounds.29,30 Please note that a small corner of the ZnO NR array on silicone hydrogel 
was not modified by 3-APS for further conjugation of the FRET pair which will be used 
as a control area for imaging analysis. 
Prior to coating QDs-based FRET sensor onto the surface of lithographically patterned 
ZnO NRs, glutaraldehyde first reacted with amino group modified ZnO NRs. Following 
that, ZnO NRs array on silicone hydrogel merged in a 20 mL CdSe solution for 3 days at 
4 °C, then washed with DI water to remove excess glutaraldehyde and CdSe/ZnS QDs. 
The obtained film was dried in the dark under vacuum to preserve sensing capabilities. 
 
 
 
 
 
 
 
 
 
ZnO NR array 
Silicone Hydrogel 
PR 
Mask 
PR Develop 
Etching 
PR remove 
UV Expose 
Patterned ZnO 
NR array on 
silicone hydrogel 
Figure 5-2. A photolithographic lift-off process for fabricating the patterned ZnO 
nanorod array on silicone hydrogel. 
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5.2.3 Synthesis of Malachite Green Dextran 
Malachite green (MG) isothiocyanate and 70,000 MW amino dextran purchased from 
Life Technologies (Burlington, Ontario, Canada) were mixed in a 0.05 M sodium 
bicarbonate buffer at pH 9.6.31 Successful conjugation of the isothiocyanate and dextran 
to form MG-dextran was verified by thin layer chromatography as shown in Figure 5-3. 
Concentration of MG-dextran (ε=105 M−1 cm−1 for malachite green at 621 nm) was 
determined by UV/Vis using the Beer-Lambert Law. 
Equation 5-1  
𝐴 =  𝑙𝑐 
Where A is the absorbance,  the molar absorptivity, l the path length, and c the 
concentration (mol/L). 
 
 
 
 
 
 
 
 
 
 
5.2.4 Synthesis and Optimization of the FRET Sensor 
Con A protein was first loaded with MG-dextran at a molar ratio of 4:1 MG-dextran to 
Con A in water and agitated for 2 hours. Following that, glutaraldehyde was added to the 
Figure 5-3. Thin layer chromatography confirmation of MG-dextran conjugation. The 
isothiocyanate and MG-dextran had a Rf value of approximately 1.0 and less than 0.25, 
respectively. 
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above solution at 1:1 molar ratio and agitated for another 2 hours. QDs were then added 
and agitated for a further 2 hours. To ensure maximum sensitivity in the presence of 
glucose, CdSe/ZnS quantum dots (QD) were conjugated to Con A loaded with MG-
dextran at weight ratios of 10:1, 5:1, 3:1, 2:1, and 1:1, respectively, to determine the 
degree of quenching and when an increase in QD weight becomes negligible to the 
change in fluorescence Figure 5-4. In this study, the optimal weight ratio of the donor 
(QDs) to enzyme (Con A) bonded with the acceptor (MG-dextran) was determined to be 
7:1 and was used throughout the study. 
In assembling the FRET sensor on ZnO silicone hydrogels, the dropwise application of 
Con A bonded with MG-dextran to the surface of QDs-decorated ZnO NRs with the aid 
of glutaraldehyde. 
 
 
Figure 5-4. FRET signal optimization. Fluorescence intensity vs the weight ratio of QDs 
to Con A loaded with MG-dextran. 
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5.2.5 Sensor measurement 
10 μL of glucose in different concentrations at pH = 7.0, 0.03 mmol/L, 0.05 mmol/L, 0.2 
mmol/L, 0.75 mmol/L, 1 mmol/L, 2 mmol/L, 3 mmol/L, were dropped on the patterned 
FRET sensors on silicone hydrogels with 30 s of interacting time. The fluorescence 
response of the patterned FRET sensors on silicone hydrogels to different concentrations 
of aqueous glucose were recorded by the fluorospectrometer with λem = 490 nm. At least 
five independent measures were conducted to measure the response of the sensor 
according to each glucose level. The standard deviation for each measured points was 
also calculated. 
5.2.6 Fluorescence sensor signal converting to image pixel intensity 
The USB powered portable MiScope, (40X, pixels = 640×480), was used to measure 
and digitally capture the fluorescence intensity of the 0.5 mg of glucose sensor 
conjugated onto ZnO NRs. 10 μL of various concentrations of glucose was added; 0.03, 
0.05, 0.2, 0.75, 1, 2, and 3 mmol/L. Glucose was allowed to react with the sensor for 5 
min prior to fluorescent measurement. The donor molecule was excited with the UV light 
built into the MiScope. 
The captured images were converted to RBG colours using Matlab as our previous 
reported results.24 Both green and red channels were applied to record the pixel intensity 
pixel values. The values of pixel intensity of the patterned sensors responding to glucose 
amounts were calculated in comparison with that of the control areas where no FRET pair 
is conjugated. The recorded fluorescence images taken by the handhold fluorescence 
microscope can be converted to the value of pixel intensity through Matlab's imaging 
process. In this imaging conversion process, the image matrix of the control area were 
used to compare with that of sensing area of the FRET sensor to obtain the value of 
pixels intensity corresponding to the concentration of glucose. 
The captured FRET sensing image with pixels ΣXY is calibrated in comparison with 
the image of the control area (lowest fluorescence signal from substrate) with pixels 
ΣX′Y′. The calibrated pixel intensity (Ip) generated from FRET sensors can be expressed 
as follows; 
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Equation 5-2 
Ip =  ΣI(XiYi) −  ΣI(Xi′Yi′), 
Where, i is the number of pixels in the chosen areas. 
5.2.7 Animal tear test 
Following the positive results of cytotoxicity (Figure 5-5), we conducted the animal test 
to evaluate the response of designed sensor to tear glucose. Four male Sprague-Dawley 
rats (Charles River Laboratories, St. Constant, QC, Canada) were housed in a 12-h 
light/dark cycle room with humidity (50%) and temperature (21.5 °C) kept constant. Rats 
were given water and chow ad libitum and made diabetic with streptozotocin (STZ; 
Sigma-Aldrich, Oakville, ON, Canada). Intraperitoneal injections of STZ (20 mg/kg) 
dissolved in a citrate buffer (0.1 M, pH 4.5) were given over five consecutive days. 
Following the confirmation of diabetes (two blood glucose readings greater than18 
mmol/L) subcutaneous insulin pellets were implanted in the abdominal region of rats. 
Rats were anesthetized with isoflurane for ease of application of the sensors to their eyes. 
Tear fluid was collected from the ocular surface with a 1 μL glass capillary tube (P1424 
SIGMA). 2 μL of rat tear sample were collected from each male Sprague-Dawley rats. 
All samples were diluted by PBS with pH = 7.0 to 7 μL. Diluted tear samples (2 μL) were 
then dropped on the FRET sensors (with five independent measures). The standard 
deviation for each measured points was also calculated. Fluorospectrometry was used to 
measure the fluorescence intensity of quantum dots (donor) after tear samples interact 
with FRET sensor for 30 secs. A blood sample was taken from the saphenous vein 
concurrently with the application of the sensor for blood glucose concentration (Freestyle 
Lite Blood Glucose Monitoring System, Abbott Diabetes Care Inc., Mississauga, 
Ontario). 
Ethics approval was obtained through the University of Western Ontario Research Ethics 
Board, in accordance with Canadian Council on Animal Care guidelines. 
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Figure 5-5. Cell viability of the FRET glucose sensor. Relative cell viability after 24 
hour incubation with various sized FRET sensor modified onto the silicone substrate. 
 
 
 
 
 
 
 
 
 
Cellular viability of the glucose sensor was conducted in the Lab of Dr. David Litchfield 
in the Department of Biochemistry of the University of Western Ontario. UTA-06 human 
osteosarcoma cells were used in this work, which were derived from the human 
osteosarcoma cell line U2-OS. The cell line was a generous gift from Dr. Christoph 
Englert, Forschungszentrum Karlsruhe, Germany.  
UTA-06 cells were cultured and grown under sterile conditions in Dulbecco's Modified 
Eagle Medium (DMEM) supplemented with 10% FBS and 100 units/mL penicillin and 
100 µg/mL streptomycin, kept at 37°C with 5% CO2. 250 000 cells were transferred into 
each well of a 24 well culture plate and incubated overnight to ensure adhesion to the 
plate. Various amounts of patterned nanostructured FRET sensors (QDs-based FERT 
sensors assembled on ZnO NRs), i.e. 0.03, 0.07, 0.10, 0.15 mg, deposited on the surface 
of silicone hydrogels with dimensions 1cm × 1cm. Samples were sterilized under UV for 
10 minutes.  
In quadruplicate, the UTA-06 cells were cultured with the above sensors deposited on 
hydrogel samples for 24 hours. After the incubation period, the sensor samples were 
removed, and a MTT cell viability assay was performed. The absorbance of the plates 
was measured at λem =490 nm, and the relative cellular viability was calculated. 
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5.2.8 Statistical Analysis 
Statistical significance was determined using GraphPad Prism (GraphPad Software Inc, 
La Jolla, CA, USA). Linear regressions were assessed. Statistical analysis of cytotoxicity 
was performed at the 95% confidence level. 
5.3 Results 
The ZnO NR array pattern was fabricated on the silicone hydrogel using it as a substrate 
by a lift-off process shown in Figure 5-1A. SEM was used to study the patterned ZnO 
NR array deposited on the synthetic silicone hydrogel as shown in Figure 5-6A and B. 
The designed pattern is made for easy identification of the captured fluorescence images 
to calibrate the pixel intensity depending on the concentration of glucose.  
The patterned ZnO NR arrays grown on the synthetic silicone hydrogel were modified 
with amino groups (-NH2) to immobilize CdSe/ZnS QDs onto the ZnO NRs. 
Glutaraldehyde first reacted with –NH2 functionalized ZnO NRs following the linkage 
formed by the reaction of glutaraldehyde with the amino group modified QDs. In Figure 
5-6C, the hexagonal rods with a smooth surface were grown on the silicone hydrogel. 
The average dimensions of the ZnO NRs are estimated at 120 ± 5 nm in diameter and 
2.00 ± 0.05 μm in length. The rough surface of the NRs can be observed when decorated 
with QDs, as shown in Figure 5-6D. Furthermore, the TEM micrograph (Figure 5-6E) 
clearly shows the QDs are decorated on the ZnO NRs. The HRTEM micrograph (Figure 
5-6F) further indicates the core-shell CdSe/ZnS QDs with 5 ± 2 nm in diameter are 
decorated on the highly crystalline ZnO NRs with a lattice fringe of 0.255 nm. Figure 5-
7 shows the FTIR spectra of the ZnO NRs with surface modification, amino modified 
QDs, and the hybrid ZnO NRs coated with QDs (ZnO NR-QDs). All samples 
demonstrate the typical –CH stretch, and –CH2 stretch in the FTIR spectra. The –C=O 
stretch at 1750 cm−1 is observed when glutaraldehyde was modified onto ZnO NRs, 
while this stretch does not show up to sample of ZnO NR-QDs. The –C=N stretch of the 
imine group, and –C=N–R located around 1620 cm−1 appears in the spectrum of ZnO 
NRs-QDs. Thus, two carbon–nitrogen double bonds (C=N), i.e. Schiff bases, were 
formed to allow QDs to coat on the ZnO NRs through the linkage of glutaraldehyde.  
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Figure 5-6. Characterization of nanomaterials by electron microscopy. A) SEM 
micrographs of patterned ZnO NRs deposited on a silicone hydrogel. The small inset is 
the photomask. B) The magnified SEM micrograph of ZnO nanorod array deposited on a 
silicone hydrogel. C) SEM micrograph of ZnO nanorods. D) SEM micrograph of QDs 
coated ZnO nanorods. E) TEM micrograph of QDs coated ZnO nanorods. F) HRTEM of 
CdSe/ZnS QDs. 
Figure 5-7. FTIR spectra of the cysteamine (Cys) modified QDs and ZnO nanorod (NR), 
and the hybrid ZnO NR coated with QDs (ZnO NR-QDs). 
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The optimization of the weight ratio of the donor (QDs) to enzyme (Con A) bonded with 
the acceptor (MG-dextran) was determined at 7:1. The photoluminescence (PL) 
properties of the nanostructured FRET transducer-coating ZnO NR array (i.e. the 
patterned FRET sensor), the nanostructured donor of the sensor (i.e. CdSe/ZnS QDs) 
were studied by a fluorospectrometer in the range of 550–700 nm. In Figure 5-8A, the 
photoluminescence (PL) spectrum of ZnO in the visible range is observed with centering 
at 628 nm.  
10 μL of aqueous glucose of various concentrations were dropped onto the patterned 
FRET sensors on silicone hydrogels with 30 seconds of interaction time. The 
fluorescence measurements were determined by fluorospectrometry. As shown in the 
illustration of Figure 5-1a, the fluorescence emission of the donor (CdSe/ZnS QDs) of 
the designed FRET sensor was quenched by the acceptor MG. The FRET emission 
(λem=652 nm) as a function of the concentration of aqueous glucose were measured. The 
relative fluorescence intensity (Ire) is calculated by using the equation below; 
Equation 5-3 
𝐼𝑟𝑒 =  𝐼’/𝐼𝑜 
where I′ is the restored intensity according to a glucose level, Io the intensity of the 
sensor without glucose, or 0 glucose concentration. Figure 5-8B shows two linear 
regions; (1) from 0.03 to 3 mmol/L; and (2) from 0 to 0.03 mmol/L. 
The fluorescence images of the patterned FRET sensors on silicone hydrogel interacting 
10 μL of various concentrations of aqueous glucose were monitored by a handheld 
fluorescence microscope. Figure 5-9A shows two fluorescence images of the patterned 
FRET sensor interacting with two samples of aqueous glucose; 0.04 mmol/L (sample A) 
and 0.4 mmol/L (sample B). The recorded images by the handheld microscope were 
converted to the readable signal through Matlab. The pixel intensity was calibrated using 
MatLab to plot the intensity as a function of aqueous glucose concentration. The 
calibrated pixel intensities of the patterned FRET sensor is clearly increasing as glucose 
increases from 0.03 mmol/L to 0.6 mmol/L as shown in Figure 5-9B. 
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Figure 5-8. Photoluminescence of the glucose sensor. (a) Photoluminescence of ZnO NR 
arrays on silicone hydrogel with/without QDs, and QDs-based fret sensors, and the UV–
vis absorption of MG. (b). A linear relationship between fluorescence intensity of the 
designed sensor and the concentration of glucose. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The rats’ tear samples were diluted 3.5 times. The patterned FRET sensor deposited on 
silicone hydrogels were used to measures the 2 μL diluted rats’ tear samples. The PL 
spectra of the sensor corresponding to glucose in tears are shown in Figure 5-10 after 
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Figure 5-9. Fluorescence images of the patterned FRET sensor on silicone hydrogel 
and the relative pixel intensities of the sensors responding to the concentrations of 
glucose. (a) Fluorescence images of the patterned FRET sensor to aqueous glucose 
with 0.04 mmol/L and 0.4 mmol/L, respectively. (b) The relative pixel intensities of 
the sensors vs. the concentration of aqueous glucose. 
interacting with rat tears. The detected glucose level in rats’ tear samples were calculated 
by using Equation 5-4. Meanwhile, the blood glucose levels to the four rats were 
measured by Freestyle Lite Blood Glucose Monitoring System, Abbott Diabetes Care 
Inc. Table 1 shows the glucose level in rats’ tear samples measured by the nanostructured 
FRET sensor as compared to the blood glucose level of the four rats. The linear 
relationship between relative fluorescence intensity and glucose concentration in the 
range of 0.03–3 mmol/L can be expressed as follows;  
Equation 5-4 
𝑌 =  0.239𝑋 +  1.132 
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Figure 5-10. Photolumenescence spectra of designed sensor responding to tear samples 
from rats with different glucose level in blood. 
 
 
Table 5-1. Glucose levels of in rat blood glucose vs tear glucose. 
Blood Glucose (mmol/L) Tear Glucose (mmol/L) 
5.3 0.14  0.03 
9.7 0.42  0.04 
12.3 0.95  0.05 
18.2 1.28  0.05 
 
 
 
 
 
 
 
 
 
 
The selectivity of the designed sensor towards glucose detection was further verified 
(Figure 5-11). 1 mM glucose in PBS solution and some possible interfering molecules, 
sucrose, fructose, mannose, lactose, maltose, mannitol, histidine, cysteine, ascorbic acid, 
and cholesterol at 1mM, were tested by the designed sensor, respectively. The relative 
sensing signal is referring to the normalization of the fluorescence intensity of the 
123 
 
 
Figure 5-11. Relative Sensing Signal (Itest sample/Iglucose) to different biomolecules. 
designed sensor responding to 1mM test sample to the sensor’s fluorescence intensity in 
the presence of 1mM glucose (Itest sample/Iglucose).  
 
 
 
 
 
 
 
 
 
 
 
5.4 Discussion 
The maximum intensity of PL spectrum of CdSe/ZnS QDs is observed at 648 nm. The PL 
spectrum of ZnO NR-QDs is dominated by the decorated QDs because of the large 
amount of QDs on a single ZnO NR, centered at 648 nm. When the acceptor of FRET 
sensor, MG-dextran, bound to QDs through Con A, the PL peak of ZnO NRs can be 
observed with centering at 652 nm; whereas the PL peak at 652 nm attributed to the 
donor (QDs) of the patterned FRET sensor is significantly suppressed. The slight redshift 
of the emission of QDs may be caused by the surface conjugation of Con A and the 
acceptor of MG-dextran. MG quenches the fluorescence signal of QDs through the FRET 
mechanism because of its broad absorbance around 650 nm. The HRTEM micrograph 
(Figure 5-6F) further indicates the core-shell CdSe/ZnS QDs with 5 ± 2 nm in diameter 
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are decorated on the highly crystalline ZnO NRs with a lattice fringe of 0.255 nm, which 
corresponds to the (0002) lattice planes demonstrated by Chen et al.32 
In the presence of glucose, the quenched fluorescence of QDs is restored after the 
addition of glucose and the fluorescence emission of the patterned FRET sensors centered 
at 652 nm increases with increasing aqueous glucose. It is noted that the concentration of 
glucose in the range of 0.03–3 mmol/L can cover the tear glucose lever of both the 
diabetes and healthy subject. The observed two linear regions can be attributed to the 
sensor’s inherent sensitivity to glucose. As Con A contains 4 binding sites for glucose, 
the initial sharp response observed corresponds to the displacement of MG-dextran as a 
result of the glucose introduction. The secondary linear zone corresponds to the 
saturation of the Con A sites as glucose concentration increases. 
The difference in pixel intensity value does not change significantly when the 
concentration of glucose is beyond 0.6 mmol/L. It is expected that a more advanced 
fluorescence microscope will be able to overcome the limit. 
The concentrations of blood glucose of the rats used in the current study were maintained 
in a range similar to patients with ‘poorly’ managed Type 1 diabetes.33 Specifically, rats 
were representative of low to moderate hyperglycemic patients with Type 1 diabetes 
mellitus under conventional insulin therapy.34 Typically blood glucose concentrations in 
patient populations with type 1 diabetes fluctuate considerably; therefore, four rats with a 
range of blood glucose concentrations were utilized in the experiment to demonstrate. As 
shown in Table 1, the small value of the calculated standard deviation of the 
measurement indicates the repeatability of the measure with our glucose sensor. 
In Figure 5-11 indicates that other saccharide molecules and some small biomolecules 
existing in tears do not interfere with the measure of glucose. Thus, our design allows 
Con A specifically to interact with saccharides with smaller molecular weight, i.e. 
glucose. 
  
125 
 
 
5.5 References 
1. Ohashi, Y., Dogru, M. & Tsubota, K. Laboratory findings in tear fluid analysis. 
Clin. Chim. Acta 369, 17–28 (2006). 
2. An, H. J. et al. Glycomics Analyses of Tear Fluid for the Diagnostic Detection of 
Ocular Rosacea. J. Proteome Res. 4, 1981–1987 (2005). 
3. Ridley, F. The Intraocular Pressure and Drainage of the Aqueous Humour. Br. J. 
Exp. Pathol. 11, 217–240 (1930). 
4. Michail, D., Vancea, P. & Zolog, N. Sur l’elimination lacrymale du glucose chez 
les diabetiques. C R Soc Biol 125, 1095–1099 (1937). 
5. Sen, D. K. & Sarin, G. S. Tear glucose levels in normal people and in diabetic 
patients. Br. J. Ophthalmol. 64, 693–695 (1980). 
6. Lewis, J. G. & Stephens, P. J. TEAR GLUCOSE IN DIABETICS. Br. J. 
Ophthalmol. 42, 754–758 (1958). 
7. Gasset, A. R., Braverman, L. E., Fleming, M. C., Arky, R. A. & Alter, B. R. Tear 
glucose detection of hyperglycemia. Am. J. Ophthalmol. 65, 414–420 (1968). 
8. Motoji, K. The glucose content of the tear fluid in normal and diabetic subjects. 
Jpn. J. Clin. Ophthalmol. 25, 1945–1950 (1971). 
9. Lane, J. D., Krumholz, D. M., Sack, R. A. & Morris, C. Tear glucose dynamics in 
diabetes mellitus. Curr. Eye Res. 31, 895–901 (2006). 
10. Boyne, M. S., Silver, D. M., Kaplan, J. & Saudek, C. D. Timing of changes in 
interstitial and venous blood glucose measured with a continuous subcutaneous 
glucose sensor. Diabetes 52, 2790–2794 (2003). 
11. Lodwig, V. & Heinemann, L. Continuous glucose monitoring with glucose 
sensors: calibration and assessment criteria. Diabetes Technol. Ther. 5, 572–586 
(2003). 
126 
 
 
12. Kvist, P. H. & Jensen, H. E. Recent advances in continuous glucose monitoring: 
biocompatibility of glucose sensors for implantation in subcutis. J. Diabetes Sci. 
Technol. 1, 746–752 (2007). 
13. O’Donnell, C., Efron, N. & Boulton, A. J. A prospective study of contact lens wear 
in diabetes mellitus. Ophthalmic Physiol. Opt. 21, 127–138 (2001). 
14. March, W., Long, B., Hofmann, W., Keys, D. & McKenney, C. Safety of contact 
lenses in patients with diabetes. Diabetes Technol. Ther. 6, 49–52 (2004). 
15. Tyagi, S., Marras, S. A. E. & Kramer, F. R. Wavelength-shifting molecular 
beacons. Nat Biotech 18, 1191–1196 (2000). 
16. Forster, T. 10th Spiers Memorial Lecture. Transfer mechanisms of electronic 
excitation. Discuss. Faraday Soc. 27, 7–17 (1959). 
17. Moschou, E. A., Sharma, B. V, Deo, S. K. & Daunert, S. Fluorescence Glucose 
Detection: Advances Toward the Ideal In Vivo Biosensor. J. Fluoresc. 14, 535–
547 (2004). 
18. Ballerstadt, R., Evans, C., McNichols, R. & Gowda, A. Concanavalin A for in vivo 
glucose sensing: a biotoxicity review. Biosens. Bioelectron. 22, 275–284 (2006). 
19. Russell, R. J., Pishko, M. V, Gefrides, C. C., McShane, M. J. & Cote, G. L. A 
fluorescence-based glucose biosensor using concanavalin A and dextran 
encapsulated in a poly(ethylene glycol) hydrogel. Anal. Chem. 71, 3126–3132 
(1999). 
20. Pickup, J. C., Hussain, F., Evans, N. D., Rolinski, O. J. & Birch, D. J. S. 
Fluorescence-based glucose sensors. Biosens. Bioelectron. 20, 2555–2565 (2005). 
21. Resch-Genger, U., Grabolle, M., Cavaliere-Jaricot, S., Nitschke, R. & Nann, T. 
Quantum dots versus organic dyes as fluorescent labels. Nat. Methods 5, 763+ 
(2008). 
127 
 
 
22. Jamieson, T. et al. Biological applications of quantum dots. Biomaterials 28, 
4717–4732 (2007). 
23. Zhang, J., Hodge, W., Hutnick, C. & Wang, X. Noninvasive diagnostic devices for 
diabetes through measuring tear glucose. J. Diabetes Sci. Technol. 5, 166–172 
(2011). 
24. Zhang, J., Wang, X., Chen, L., Li, J. & Luzak, K. Harnessing a nanostructured 
fluorescence energy transfer sensor for quick detection of extremely small amounts 
of glucose. J. Diabetes Sci. Technol. 7, 45–52 (2013). 
25. Chen, L., Bao, Y., Denstedt, J. & Zhang, J. Nanostructured bioluminescent sensor 
for rapidly detecting thrombin. Biosens. Bioelectron. 77, 83–89 (2016). 
26. Chen, Y., Tse, W. H., Chen, L. & Zhang, J. Ag nanoparticles-decorated ZnO 
nanorod array on a mechanical flexible substrate with enhanced optical and 
antimicrobial properties. Nanoscale Res. Lett. 10, 106 (2015). 
27. Lee, C.-M. et al. Surface engineering of quantum dots for in vivo imaging. 
Nanotechnology 21, 285102 (2010). 
28. Kim, J., Conway, A. & Chauhan, A. Extended delivery of ophthalmic drugs by 
silicone hydrogel contact lenses. Biomaterials 29, 2259–2269 (2008). 
29. Kim, J. Y. & Osterloh, F. E. ZnO-CdSe nanoparticle clusters as directional 
photoemitters with tunable wavelength. J. Am. Chem. Soc. 127, 10152–10153 
(2005). 
30. Costenaro, D., Carniato, F., Gatti, G., Bisio, C. & Marchese, L. On the Physico-
Chemical Properties of ZnO Nanosheets Modified with Luminescent CdTe 
Nanocrystals. J. Phys. Chem. C 115, 25257–25265 (2011). 
31. McCartney, L. J., Pickup, J. C., Rolinski, O. J. & Birch, D. J. Near-infrared 
fluorescence lifetime assay for serum glucose based on allophycocyanin-labeled 
concanavalin A. Anal. Biochem. 292, 216–221 (2001). 
128 
 
 
32. Chen, C. et al. Enhanced Raman scattering and photocatalytic activity of Ag/ZnO 
heterojunction nanocrystals. Dalton Trans. 40, 9566–9570 (2011). 
33. Nathan, D. M. The diabetes control and complications trial/epidemiology of 
diabetes interventions and complications study at 30 years: overview. Diabetes 
Care 37, 9–16 (2014). 
34. Melling, C. W. J. et al. A model of poorly controlled type 1 Diabetes Mellitus and 
its treatment with aerobic exercise training. Diabetes Metab. 39, 226–235 (2013). 
 
 
 
 
 
 
  
129 
 
 
CHAPTER 6  
The final chapter of this thesis revisits the motivation, research objectives, and provides a 
summary of the important findings and conclusions of Chapters 2-5. Limitations and 
future studies for theranostics motivated by this work presented in this thesis will be 
discussed. 
6 CONCLUSION AND FUTURE DIRECTIONS 
6.1 Overview of Rationale and Research Questions 
Theranostics is a constantly evolving field, providing new opportunities in developing 
new healthcare technologies at an affordable price.1 The application of nanoparticles is 
highly suitable for theranostics as it provides material-based properties, a framework for 
personalized medicine, and high-surface area to volume fitting for surface 
modifications.2–4 The goal of theranostics is to concurrently provide biomedically 
relevant diagnostic information and exert a pharmaceutical effect and overcome potential 
limitations of current technology. Applications of theranostic applications aim to enhance 
drug carriers, biosensors, and imaging entities. 
For instance, gadolinium contrast agents have been proven to cause adverse effects if in 
its free ionic form rather than chelated.5,6 Through transmetallation, the Gd ions can be 
replaced in the chelator by Fe, Ca, Zn, and Cu ions, where thereby the Gd may freely 
interfere with cation channels leading to splenic degeneration, liver necrosis, etc.5 Cases 
of neurotoxicity have also been reported.7  
Drug delivery can be affected by natural barriers such as the hepatic first pass, the blood 
brain barrier, and diffusion through fenestrations causing a loss of therapeutic 
concentration and therefore shortening the duration of treatment or not achieving the 
therapeutic threshold to exert a therapeutic response.8,9  
The application of nanoparticles for theranostics is dependent its functionalization with 
targeting ligands, proteins, and antibodies for specificity and functionality.10 It is already 
understood nanoparticle possess far superior properties that can address the shortcomings 
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of current biomedical technologies. However, as a whole, nanoparticles and its 
functionalization is not yet understood with regards to functionalization strategies and 
cellular interactions.  
In response to these unknowns of theranostic applications, the overarching objective of 
this thesis was to assess and understand nanoparticle-protein interactions at the molecular 
and cellular level to provide pertinent developments in pushing the area of 
nanotechnology forward for biomedical applications. The specific research questions 
investigated here include: 1) Is our theranostic model composed of an organic 
nanoparticle drug carrier core hybridized with inorganic fluorescent nanoparticles and 
functionalized with anti-human antibodies suitable for drug delivery? (Chapter 2); 2) 
What are the repercussions of functionalization strategies on cell viability? (Chapter 3); 
3) Can Gd-based UCNPs functionalized with anti-VEGF exert the same anti-angiogenic 
therapeutic effect as anti-VEGF while simultaneously provide upconversion fluorescence 
and MRI tracking potential? (Chapter 4); 4) Can non-invasive nanoparticle-protein 
biosensors provide high selectivity and sensitivity for the quantification of glucose? 
(Chapter 5). 
6.2 Summary and Conclusions 
In Chapter 2, we quantitatively assessed gelatin-based nanospheres hybridized with 
CdSe/ZnS/cysteamine QDs and functionalized with anti-human IgG Fab for non-specific 
targeted drug delivery. Assessed in UTA-6 osteosarcoma cells, the functionalized 
nanoparticles of 480 ± 50 nm exhibited an increase of 50% cellular interaction compared 
to non-functionalized particles (p =0.0023). The relative viability at a concentration 40 
µg/mL remained above 80% with no significant difference (p = 0.8074) between the 
different samples. The results indicate our model is an effective model for maximizing 
the abilities of drug-loaded gelatin nanoparticles for targeted drug delivery and imaging. 
In Chapter 3, we contrasted and compared the repercussions of modification strategies of 
our gelatin-based nanoparticle (GNP) model. With the same modifications as mentioned 
on Chapter 2, we assessed the order of modification first with either QDs or anti-IgG and 
followed by the other. PEGylation was also performed and assessed to potentially 
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increase compatibility. The results indicated modification strategy did not significantly 
impact the size but rather the addition of anti-IgG that significantly increased the size 
compared to the bare GNP (p < 0.0001).  The amount of QDs hybridized (p = 0.1000) 
and anti-IgG bioconjugated (p = 0.727) did not differ significantly. Through live cell 
imaging, the modified GNPs were able to be fluorescently detected and located with 
UTA-6 cells through a z-stack. Cell viability of UTA-6 osteosarcoma cells differed 
significantly (p < 0.05) between Path A (ie: QD first followed by anti-IgG) and Path B 
(ie: anti-IgG first followed by QD). Path A modified GNP remained above 80% viability 
even when treated with 40 µg whereas Path B modified GNP decreased to below 50% 
viability. PEGylation significantly decreased Path A viability slightly (p = 0.0034) while 
remaining above 70% at 40 µg, whereas Path B viability increased slightly (p = 0.0019) 
as a result but did not reach above 60%. The results implicate the components and 
modification strategies must be considered when developing nanoparticle technology for 
therapeutic applications as the final product may possess significant repercussions which 
may inhibits its full potential. 
In Chapter 4, we quantitatively assessed an upconversion nanoparticle model 
functionalized with anti-VEGF for the treatment of pathological angiogenesis with 
bimodal tracking via upconversion fluorescence and magnetic resonance. We verified 
upconversion fluorescence via a spectrophotometer outfitted with a NIR laser and MRI 
compatibility with VSM and a 3 T MRI. Relative viability was assessed in HUVECs with 
various concentrations of Gd-UCNPs, Gd-antiVEGF UCNPs, and the anti-VEGF 
equivalent. Gd-UCNP has a significantly higher viability compared to the Gd-antiVEGF 
UCNPs (p = 0.0114) when treated with up to 300 µg/mL of nanoparticles. Viability at 10 
and 100 µg/mL of UCNPs or anti-VEGF indicated Gd-UCNPs yielded a higher viability 
in comparison to both its anti-VEGF functionalized counterpart and the anti-VEGF 
equivalent (p < 0.05). We were able to quantify the observed morphological changes with 
confocal microscopy as a result of the treatments. Anti-VEGF based treatments produced 
a significantly shorter cell length (p < 0.0001) than Gd UCNPs. The results suggest there 
were no significant difference between anti-VEGF and the Gd-antiVEGF except for the 
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bimodal imaging properties. This suggests the Gd-antiVEGF model is suitable for 
theranostic applications as an alternative to bare anti-VEGF. 
In Chapter 5, we assessed a non-invasive method of glucose detection in tears as a 
reflection of blood glucose using a FRET quenching mechanism. Con A covalently 
bonded with QDs with glutaraldehyde was loaded with MG-dextran. The MG-dextran 
acts to quench the QDs signal until glucose is introduced. As a result, the MG-dextran 
was displaced from Con A as glucose had demonstrated a higher affinity to increase the 
detected fluorescent signal. The biosensor was anchored to a ZnO nanorod substrate for 
stability. The FRET sensor demonstrated both selectivity and sensitivity to detect glucose 
between 0.03 mM and 3 mM. The tear glucose of diabetics is noted to by > 0.35 ± 0.04 
mM. Our results verified our sensor was able to measure tear glucose in a volume as little 
as 2 µL in a short span of time. 
In summary, we demonstrated the importance of proteins and antibodies to provide 
functionality to nanoparticles and provided nanoparticle solutions to address 
shortcomings of current biomedical technology. We demonstrated 2 potential methods of 
drug delivery a) drug carrier modified with fluorescent nanoparticles and antibodies for 
selectivity; b) therapeutic antibodies directly conjugated onto the surface of MR 
compatible and upconversion trackable nanoparticles. We also provided an alternative to 
invasive glucometry via a non-invasive tear glucose biosensor with high selectivity and 
sensitivity for changes in glucose measured by fluorescence. 
6.3 Limitations 
In this section, we address some limitations of the technologies presented in Chapters 2-
5. A description of both study specific limitations and technological limitations will be 
discussed. 
6.3.1 Study Specific Limitations 
Engineering Large Gelatin Nanospheres Coated with Quantum Dots for Targeted 
Delivery to Human Osteosarcoma Cells with Enhanced Cellular Internalization (Chapter 
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2) and Cellular interaction influenced by surface modification strategies of gelatin-based 
nanoparticles (Chapter 3) 
In the studies presented in Chapters 2 and 3, the inverted microscope outfitted for live 
imaging used to obtain cell images did not possess the ideal imaging conditions for 
accurate identification of the QD modified GNs and GNPs. As evidenced in the images, 
the fluorescent signal obtained was observed to be oval in nature. This observed 
phenomena, an airy disk, is resultant of the microscope collecting out of focus light above 
and below the objective focal plane.11 A significant amount of out of focus fluorescence 
emission was delivered through the aperture to produce the airy disk. As a result, the 
localization of the fluorescent nanoparticles was not accurate as assumptions had to be 
made to assess the internalization and surface interactions. We evaluated the particle 
based on the centre of the emission relative the surface of the cell, the plane of which the 
cell surface was in focus. 
Bimodal imaging compatible theranostic nanoparticles for anti-angiogenic treatment 
(Chapter 4) 
In the study presented in Chapter 4, the observed HUVECs did not form a uniform 
monolayer as expected when angiogenesis was induced with PMA. The observed cells 
tended to aggregate into distinct groups and overlap leading to inaccurate measures of 
cell morphology at times. Furthermore, the cells did demonstrate sprout tip formation and 
elongation as reported by Osaki et al.12 but extensive connected vascular networks as 
demonstrated by Nagamori was not observed after 24 hours.13 This could be been 
resultant of an underestimation of seeding density  causing isolated pockets of cells. As a 
result, we were unable to quantify the density of the network or growth of the network. 
However, the results were conclusive of the anti-angiogenic properties of the Gd-
antiVEGF UCNPs to mitigate angiogenesis by assessing the elongation of the cells as 
proof of the migration and sprout tip formation during angiogenesis. The decreased 
viability was proof of the anti-prolific response to the anti-VEGF treatments. 
Nanostructured biosensor for detecting glucose in tear by applying fluorescence 
resonance energy transfer quenching mechanism (Chapter 5) 
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In the study presented in Chapter 5, the murine model compatibility with the sensor area 
was a challenge. Firstly, the biosensor modified on to the ZnO nanorod substrate was 
applied in its dehydrated form. The substrate was unable to conform to the shape of the 
murine eye during direct application. Secondly, the biosensor distribution localized was 
caused during the conjugation process to the ZnO as the biosensor was applied as a 
droplet onto the substrate. The distribution of the sensor droplet was dependent on the 
surface tension. As a result, adjustments were required to ensure the full content of the 
biosensor was exposed to the tear glucose. This application may have caused slight 
discomfort to the mouse while under sedation. 
6.3.2 General Limitations 
Pertinent to Chapters 2, 3, and 5, we acknowledge the QDs have not been perfected and 
therefore additional investigations are required to validate them as candidates for in vivo 
biomedical applications. QDs, possess the fluorescent qualities suitable for biomedical 
applications as they are resistant to photobleaching, highly stable as a whole, and possess 
tunable fluorescence.14,15 However, on a deeper level, QDs even when capped for 
enhanced stability are subject to the dissociation of the heavy metal ion constituents from 
the core in response to acidic pH and aerobic conditions.16 The leaching of Cd ions can 
occur through the ZnS shell to cause cytotoxicity at concentrations as low as 1 nM in 
vitro.17 The incorporation of the protein metallothionein into the model may sequester 
low levels of Cd ions into an inert complex.18 Another core concern is the application of 
high energy photons to stimulate the fluorescent response. Side effects include 
genotoxicity and mutagenesis resulting in carcinogenesis.19–21 As demonstrated with gel 
electrophoresis, shorter excitation wavelengths, and longer irradiation periods are known 
to induce significant damage as well.22  
In Chapter 4 we inclined to shift to UCNPs as the multi-photon NIR infrared excitation 
possesses the ideal spectral and optical window for biological imaging.23,24 One limitation 
UCNPS for bimodal compatible imaging in MRI and fluorescence is the optimization of 
lanthanide dopants essential to its function. The efficiency of its desired effects come as a 
tradeoff between size and the amount of lanthanides doped. A larger diameter UCNPs 
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theoretically can hold a larger concentration of lanthanide dopants. However, is the size 
tradeoff worth it if there are biological repercussions when introduced in vitro or in vivo. 
Furthermore, the concentration of individual lanthanide dopants can be adjusted to suit 
the individual needs of the imaging modality under consideration. It is possible with 
further investigation to refine and optimize the dopants concentrations for bimodal 
applications with the desired properties suitable for biomedical applications. 
As discussed in Chapters 2-4, antibody and therapeutic protein bioconjugation to 
nanoparticles are effective for cell targeting and treatment. However, they possess 
limitations of their own. Steric hindrance and spatial orientation of the protein of choice 
is important for execution of its function. In our direct conjugation method, steric 
hindrance may have limited the amount of antibodies and proteins conjugated on the 
surface, yet at the same time limit access of the nanoparticle surface laden functional 
groups to cellular processes which may negatively impact cellular processes as reported 
by Kim et al.25 Steric hindrance of protein conjugation can be addressed with the addition 
of linker molecules which extend from the surface of the nanoparticles themselves.26 
These same molecules may also be used to spatially orientate antibodies to maximize 
their potential and function.27 
6.4 Future Directions 
6.4.1 Upconversion nanoparticle based contact lens biosensor for 
non-invasive glucose detection 
Our results in Chapters 4 and 5 prompted us revisit the biosensor laden substrate using a 
contract lens compatible material and UCNPs for signal generation. The results strongly 
support the advantages of using the Er, Yb lanthanide pair for the biosensor signal. Using 
a similar construct of Con A loaded with MG-dextran, we conjugated the UCNPs with 
glutaraldehyde to form a stable covalent bond prior to loading directly onto the surface of 
the silicone hydrogel. Our foundation in nanoparticle-protein manipulation and 
functionalized aided in the optimization of conditions for suitable for glucose sensing 
with UCNPs. 
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Figure 6-1. UCNP-based glucose sensor. A) Scanning electron micrograph of the 
biosensor loaded onto the surface of the silicone hydrogen. The Con A and UCNPs can 
be clearly seen in the image. B) Optimization curve of the UCNP to Con A weight ratio. 
R2 = 0.9976. 
Our preliminary results as shown in Figure 6-1 demonstrates the potential for the 
UCNPs-based sensor for glucose detection. We were able to confirm not only the 
deposition of the sensor onto the silicone hydrogel via scanning electron microscopy, but 
the Con A and the UCNPs as well (Figure 6-1A). We were able to generate an 
optimization curve for the Gd-UCNPs to Con A ratio as well (Figure 6-1B). 
   
 
 
 
 
 
 
 
 
 
We aim to evaluate the performance in a proof-of-concept study to: 
a) Employ NIR lasers to measure changes in glucose within the therapeutic optical 
window (700 nm – 1700 nm)23 
b) Develop a wearable version of the biosensor for direct glucose sensing 
The next steps in the study involve refining silicone model as whole to minimize the 
potential dissociation of the biosensor from the surface and design the biosensor 
orientation on the silicone hydrogel curb impeding of vision. As well, glucometric data 
will be obtained in vitro and in vivo with a murine model. 
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6.4.2 Biomedical collaborations for treatment design 
The next steps in developing biomedically relevant nanoparticle technology is to seek 
collaborations with clinicians and other research groups dedicated to disease treatment 
research. The merriment of interdisciplinary knowledge provides an understanding of the 
disease treatment regimen of various pathologies and the limitations that nanoparticles 
can address. As we have discussed previously, nanoparticles are capable of being 
effective drug carriers that can overcome physiological barriers and can localize 
therapeutics to an area of interest. By understanding the conditions for an effective 
treatment of current pathologies, nanoparticles are adequate entities to be tailored and 
personalized for specific diseases or patient needs. 
6.5 Significance and Impact 
Although the physical and material-based properties of nanoparticles have been 
extensively studied, there is a lack of understanding the consequences at the cellular level 
when they are personalized for specific applications or pathological treatments. Using 
various combinations of nanoparticles (organic or inorganic) functionalized with proteins 
and antibodies to provide purpose, various theranostic applications were assessed; drug 
delivery with two different models and high sensitivity non-invasive glucose sensing. 
This thesis significantly advances our understanding of the nanoparticle and protein 
interactions as the future of biotechnology to combine diagnostics and therapeutics into 
one practical entity that can be tailored to individual needs. The studies presented in this 
thesis provides unequivocal evidence that nanotechology can circumvent the challenges 
of modern technology through increased stability of metal ions, potentiate a higher or 
induce a similar therapeutic response, and provide a safer alternative for biosensing and 
drug delivery. 
Additionally, this thesis increased the fundamental knowledge of theranostic model 
design and functionalization strategies to optimize and maximize the potential of 
nanoparticles for various applications. 
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